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Abstract
POST-TRANSPLANT HEPATIC GRAFT FIBROSIS
IN PEDIATRIC LIVER-INCLUSIVE TRANSPLANT RECIPIENTS
Hanh Thi Diem Vo, M.D., Ph.D.
University of Nebraska Medical Center, 2021
Hepatic graft fibrosis is a common histologic finding following pediatric liver transplant
(LT) that may affect the long-term graft outcome. Hence, it is essential to identify
hepatic graft fibrosis at a stage where fibrosis is not yet clinically apparent but has the
potential for progression to initiate appropriate intervention and prevent its
progression. Liver biopsy is the gold standard for fibrosis staging, but it is invasive,
requires general anesthesia in children, and has potential complications. Our long-term
goal is to implement non-invasive tests to assess and monitor the progression of hepatic
graft fibrosis in liver-inclusive transplant children. The work presented in this
dissertation is the initial step to achieving this goal. We aimed to (1) understand the
prevalence of and potential risk factors for hepatic graft fibrosis in combined liver-small
bowel transplant (LSBT) compared to LT children, and (2) investigate the diagnostic
performance of the newer elastography technique 2D-shear wave elastography (2DSWE) and selected serum markers for assessing hepatic graft fibrosis. We demonstrated
that LSBT children could also develop hepatic graft fibrosis; its prevalence did not
significantly differ from LT children (70.2% vs. 81.6%, p=0.19), but the predictors
differed. Our scoping review of the limited number of available studies examining the

usefulness of non-invasive tests for assessing hepatic graft fibrosis in LT children
suggested that transient elastography in the pediatric LT setting had similar diagnostic
value and limitations as in the non-transplant setting and current serum markers had
unsatisfactory diagnostic accuracy. In the work presented here, we demonstrated that
serum markers AST-to-platelet ratio index and Fibrosis-4 score (FIB4), especially graft
FIB4 (calculated based on the hepatic graft's age), can accurately predict significant
hepatic graft fibrosis in our LT/LSBT cohort; 2D-SWE had good diagnostic performance
and may serve as a valuable adjunct tool for detecting significant hepatic graft fibrosis,
especially when combined with these serum markers. We also reviewed the role of
serum micro-RNA in the pathogenesis of hepatic fibrosis and its diagnostic application as
potential novel biomarkers for the detection of hepatic graft fibrosis in the future.
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Introduction
Liver transplant (LT) is a standard treatment for patients with end-stage liver disease.
Small bowel transplant is a lifesaving treatment and a standard of care for patients with
irreversible intestinal failure. Combined liver-small bowel transplant (LSBT) is the only
long-term treatment option for patients with intestinal failure and advanced intestinal
failure-associated liver disease. Pediatric LT is highly successful, with 1-year, 5-year, and
10-year primary graft survivals consistently reported at 94%, 91%, and 88%,
respectively.1 In contrast, although clinical outcomes of LSBT children have improved
over the past decade, patient and graft survivals in LSBT remain inferior compared to LT,
with 1-, 5-, and 10-year patient and graft survivals of 77%, 58%, 47% and 71%, 50%,
41%, respectively.2 Long-term hepatic graft outcome depends on multiple factors, such
as disease recurrence, biliary and/or vascular complications, de novo autoimmune
hepatitis, graft dysfunction, and chronic rejection. Additionally, long-term complications
that have been described in pediatric LT, such as chronic graft hepatitis and hepatic
graft fibrosis, might contribute to graft loss and subsequent re-transplantation in longterm pediatric LT survivors.3-6
Hepatic graft fibrosis is a common histologic finding in LT children. 3,7,8 It has been
reported as early as 12 months following pediatric LT in serial protocol biopsies, even in
patients with normal graft function and normal or nearly normal transaminases.3,7 Its
prevalence significantly increases over time, ranging from 31-52% at one year to 65-91%
at 5 years, and by 10 years, 29-50% progress to advanced fibrosis or cirrhosis.4,7,9
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Consequently, this may affect long-term graft and patient outcomes. While the natural
history and pathogenesis of hepatic graft fibrosis remain unclear, previous studies
suggested that idiopathic chronic hepatitis and hepatic graft fibrosis might be associated
with donor-specific antibody (DSA) positivity,5 and may improve or be prevented with
increased immunosuppression.7,10,11 A recent publication also demonstrated that
autoantibody and DSA positivity are associated with histologic alterations of graft
dysfunction in pediatric LT recipients.12 Thus, it is essential to identify hepatic graft
fibrosis at an early stage and understand its potential risk factors to initiate appropriate
intervention and prevent its progression.
Liver biopsy is the gold standard diagnostic test for fibrosis assessment and
staging. Yet, it is invasive, requires general anesthesia in children, and has potential
severe complications (hemopneumothorax, bleeding, infection, bowel perforation, bile
leak, etc.).13 The specimen represents roughly only 1/50,000 of the liver volume, and
there is intraobserver and/or interobserver variability on microscopic interpretation,
with a reported 25% discordance rate in staging among pathologists.13-16 Therefore, it is
essential to develop non-invasive tools with acceptable diagnostic accuracy to assess
hepatic graft fibrosis in these pediatric transplant recipients.
Our long-term goal is to implement non-invasive tests to assess and monitor the
progression of hepatic graft fibrosis in pediatric liver-inclusive transplant recipients
(Figure 1). The work presented in this dissertation is the initial step to achieving this
goal. We aimed to (1) understand the prevalence of and potential risk factors for
hepatic graft fibrosis in combined LSBT compared to isolated LT children, and (2)
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investigate the diagnostic performance of non-invasive tests, such as the newer
elastography technique 2D-shear wave elastography (2D-SWE) and selected serum
markers, for assessing hepatic graft fibrosis. Chapter 1 describes the prevalence of and
potential risk factors for hepatic graft fibrosis in LSBT compared to LT children (Figure 2).
In Chapter 2, we systematically review the current published literature on the diagnostic
accuracy of available non-invasive methods (i.e., elastography techniques and serumbased fibrosis markers) for assessing hepatic graft fibrosis, exclusively in pediatric LT
recipients. Chapter 3 describes the diagnostic performance of the newer elastography
technique 2D-SWE and selected serum-based fibrosis markers for assessing hepatic graft
fibrosis in LT/LSBT children (Figure 2). Finally, in Chapter 4, we review the role of serum
miRNA in the pathogenesis of hepatic fibrosis and its diagnostic application as potential
novel biomarkers for detecting hepatic graft fibrosis in the future.

Figure 1. Conceptual framework to investigate hepatic graft fibrosis in LT/LSBT children
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Figure 2. Study flowchart to investigate hepatic graft fibrosis in LT/LSBT children
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Chapter 1: Hepatic Graft Fibrosis in Pediatric Liver-Inclusive
Transplant Recipients
Background
Previous studies have investigated potential risk factors for hepatic graft fibrosis
following pediatric LT,4,9 but the prevalence of and risk factors for hepatic graft fibrosis
following pediatric LSBT have not been examined or compared to pediatric LT (Figure 1).
Children with LT, especially those receiving technical variant grafts (i.e., split, reducedsize, or living-related grafts), might have higher rates of vascular and/or biliary
complications than those with LSBT, whereas children with LSBT often require higher
levels of immunosuppression, and consequently, might have higher rates of infectious
complications and post-transplant lymphoproliferative disorders (PTLD). Additionally,
children with LSBT might require prolonged parental nutrition (PN) after transplant,
which can result in PN-related liver injury. Hence, we hypothesized that the natural
history and potential risk factors for the development of hepatic graft fibrosis in children
with LSBT might differ from those with LT. This study aimed to determine the
prevalence of hepatic graft fibrosis in LSBT children and investigate potential predictors
for hepatic graft fibrosis in LSBT versus LT children.

Methods
Study population and design
This retrospective cohort study was approved by the University of Nebraska Medical
Center (UNMC) Institutional Review Board. We included all children younger than 19
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years between January 2000 and December 2018 who had received a primary LT or LSBT
and had a liver biopsy performed at least six months post-transplant for clinical
indications. A chart review was conducted to extract relevant clinical information,
laboratory data, and medical procedures at the time of transplant and liver biopsy.
Data collection
Clinical information included patient demographics, patient's age at transplant,
ethnicity/race, primary liver and/or intestinal disease, recipient cytomegalovirus (CMV)
status (determined by serum CMV DNA, or CMV serology in a minority of children older
than 18 months), ABO blood type compatibility, liver graft type, donor-to-recipient age
ratio, allograft cold ischemia time (CIT), and donor liver biopsy if performed. History of
post-transplant PN use was also collected if the patient received PN greater than 30
days post-transplant, or if PN was later restarted and then continued for greater than 30
days due to feeding intolerance or small bowel graft failure. Post-transplant data
included post-transplant liver complications (acute liver rejection, chronic liver rejection,
vascular and biliary complications, PTLD, viral hepatitis), post-transplant intestinal
complications (acute intestinal rejection, chronic intestinal rejection, PTLD), and
immunosuppression regimen. Laboratory data included aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and platelet count at the time of liver biopsy to
calculate serum-based fibrosis markers: AST/ALT ratio, AST-to-platelet ratio index
(APRI), and Fibrosis-4 score (FIB4, which was calculated based on the patient’s age at
the time of biopsy, AST, ALT, and platelet count [discussed in Chapter 2]). Immunological
data included pre-transplant panel reactive antibodies, post-transplant DSA, and
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autoimmune antibodies (antinuclear antibody, anti-smooth muscle antibody, anti-liverkidney microsomal type 1 antibody, perinuclear anti-neutrophil cytoplasmic antibody).
The immunosuppressant level at the time of liver biopsy was averaged from 3
consecutive levels taken within 3 months before the liver biopsy. Histologically, liver
fibrosis was assessed using Masson's trichrome stain and staged according to the BattsLudwig system, which classifies fibrosis into five stages: F0, no portal fibrosis; F1, portal
fibrosis without septa; F2, portal fibrosis with few septa; F3, portal fibrosis with
numerous septa, no cirrhosis; and F4, cirrhosis. The fibrosis was further defined as
clinically significant fibrosis if it was staged F2, or advanced fibrosis if it was staged F3.
Where available, liver biopsy specimens were retrieved and reviewed by a single,
experienced transplant pathologist for fibrosis assessment. If a patient had multiple
biopsies at different time points, the fibrosis stage was documented at the most recent
biopsy.
Post-transplant protocol
The standard immunosuppression protocol consisted of corticosteroids for all transplant
recipients and additional basiliximab- or thymoglobulin-based induction in LSBT
children, followed by tacrolimus-based maintenance therapy. Other
immunosuppressants, such as sirolimus, everolimus, or mycophenolate mofetil, were
additionally used in patients with rejection, renal dysfunction, or tacrolimus-related side
effects. Target tacrolimus trough levels (ng/mL) in LSBT and LT patients were 15-20 and
10-12 during the first month after transplant, 10-15 and 8-10 from 1-6 months, 5-10 and
5-8 from 6-12 months, and 3-5 afterward, respectively. All patients received 20 mg/kg
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(maximum 1 gram) intravenous methylprednisolone intra-operatively, continued with a
taper schedule until postoperative day 6, and then remained on oral prednisone at 0.25
mg/kg/d for one year in LSBT children, or 6 months in LT children. In LSBT,
corticosteroids were subsequently weaned to every other day for 1-2 months at oneyear post-transplant, and then discontinued on a case-by-case basis if there was no
rejection during the previous 6 months. All children received prophylactic medications
for the prevention of Pneumocystis jirovecii pneumonia and CMV infection, and a
subgroup of LSBT children who had splenectomy at the time of transplant also received
lifelong daily oral penicillin or amoxicillin for the prevention of pneumococcal infection,
as previously described.17 All patients underwent serial liver ultrasounds with Doppler as
part of routine postoperative follow-up or thereafter when clinically indicated for
evaluation of abnormal liver tests. Further investigation with magnetic resonance
cholangiopancreatography or percutaneous transhepatic cholangiography was indicated
if there were concerns for biliary complications (i.e., anastomotic and/or nonanastomotic biliary strictures, bile leaks, recurrence of primary biliary disease, etc.).
Liver biopsy was only performed when clinically indicated, i.e., for elevated
transaminases to rule out acute liver rejection or other etiologies. Additionally, in LSBT
children, protocol biopsies of the small bowel allograft were performed weekly during
the first month post-transplant for intestinal rejection surveillance.
Statistical analysis
Data were analyzed using SPSS version 25.0 (Chicago, IL, USA) and SAS University Edition
(SAS Institute, Cary, NC, USA). Patient characteristics were reported as frequencies and
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percentages, and medians and interquartile ranges (IQR), as appropriate. Univariate
analyses were performed in LSBT and LT children separately to examine potential
predictors associated with significant hepatic graft fibrosis (F2). The examined
predictors were age at transplant, gender, ethnicity/race, ABO compatibility, recipient
CMV status, CIT, donor-to-recipient age ratio, maintenance immunosuppression, history
of post-transplant PN use, history of post-transplant complications (acute liver rejection,
chronic liver rejection, vascular complications, biliary complications, PTLD in the liver),
and serum-based fibrosis markers (AST/ALT ratio, APRI, and FIB4). Groups of LSBT and
LT were compared using the chi-square test or Fisher’s exact test for categorical
variables and t-test or Mann-Whitney U test for continuous variables, as appropriate.
The Kaplan-Meier method was performed to estimate the probability of developing
hepatic graft fibrosis over time, using the log-rank chi-square test to compare the curves
between LT and LSBT children; the censoring time was obtained from the time of
transplant to the time of liver biopsy. To identify predictors associated with significant
hepatic graft fibrosis, variables that were found to be statistically significant by
univariate regression analyses or appeared to have clinical significance were entered
into a Cox proportional hazards regression model, which was performed separately in LT
and LSBT children. The backward stepwise procedure was used to determine predictors
associated with significant hepatic graft fibrosis, with the level of significance at 0.10 for
the covariates to remain in the model. The appropriateness of the Cox proportional
hazards assumption was checked using the goodness-of-fit proportional hazards testing
approach. The hazard ratio for each specific covariate was computed as the exponential

10

of the regression coefficient. A p-value was given for tests that evaluated whether the
regression coefficients equaled zero. A p-value of less than 0.05 was considered as the
level of significance for all tests unless otherwise stated.

Results
Patient characteristics
A total of 96 children (47 LSBT, 54 females) met the inclusion criteria. Table 1
summarizes patient characteristics by type of transplant. The median (IQR) age at
transplant was 1.0 (1.1) years in LT vs. 1.3 (1.1) years in LSBT children (p=0.01). The
median (IQR) follow-up after transplant was 12.8 (5.4) years in LT children, compared to
10.5 (9.7) years in LSBT patients (p=0.06). There was no significant difference in gender
and ethnicity/race between the two groups. The most common primary liver disease
was biliary atresia in the LT group, whereas most LSBT children had intestinal failureassociated liver disease. Of note, 14 children in the LT group had short-bowel syndrome
and underwent primary LT for intestinal failure-associated liver disease; among these, 5
patients failed to achieve full enteral autonomy after LT and subsequently required a
secondary LSBT. These 5 children also developed intestinal failure-associated liver
disease in their primary liver grafts.
The majority of the patients were maintained on tacrolimus-based
immunosuppression. There was a trend toward a significantly higher percentage of
patients who remained on low-dose steroids at the time of liver biopsy in LSBT
compared to LT children (36.2% vs. 18.4%, respectively, p=0.05). However, there was no
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significant difference in the median immunosuppressant level or steroid dose at the
time of liver biopsy between the two groups (Table 1).
Table 1. Patient characteristics by type of transplant
LT (n=49)

LSBT (n=47)

p-value

1.0 (1.1)
12.8 (5.4)
23 (46.9)

1.3 (1.1)
10.5 (9.7)
31 (66.0)

0.01
0.06
0.06
0.22

28 (57.1)
21 (42.9)

21 (44.7)
26 (55.3)

Clinical characteristics
Age at transplant (years), median (IQR)
Follow-up after transplant (years), median (IQR)
Female, n (%)
Ethnicity/Race, n (%)
White
Other
Primary liver disease, n (%)
Biliary atresia
Acute liver failure
Intestinal failure-associated liver disease
Other
Primary intestinal disease, n (%)
Necrotizing enterocolitis
Intestinal atresia
Gastroschisis
Volvulus/malrotation
Other
Liver graft type, n (%)
Full-size liver
Reduced-size/split liver
Living-related liver
Positive recipient cytomegalovirus status, n (%)
Donor-to-recipient age ratio, median (IQR)
Cold ischemia time (hours), median (IQR)
ABO compatibility, n (%)
Identical
Compatible
History of PN after transplant, a n (%)
Prolonged  30 days post-transplant, n (%)
Restarted and continued  30 days, n (%)
Immunosuppression
Maintenance immunosuppression, n (%)
Tacrolimus only
Tacrolimus and other b
Non-tacrolimus
Immunosuppressant level (ng/mL) at the time of liver
biopsy, median (IQR)

n/a
17 (34.7)
7 (14.3)
14 (28.6)
11 (22.4)

45 (95.7)
2 (4.3)

9/14 (64.3)
2/14 (14.4)
1/14 (7.1)
1/14 (7.1)
1/14 (7.1)

12 (26.1)
8 (17.4)
11 (23.9)
5 (10.9)
10 (21.7)

n/a

n/a
24 (50.0)
17 (34.7)
8 (16.3)
28 (57.1)
3.5 (15.0)
7.6 (3.0)

20 (42.6)
0.4 (0.4)
8.3 (2.2)

42 (93.3)
3 (6.7)
12 (24.5)
12 (24.5)
3 (6.1)

43 (93.5)
3 (6.5)
38 (80.9)
35 (74.5)
6 (12.8)

36 (73.5)
10 (20.4)
3 (6.1)
4.3 (3.6)

27 (57.4)
13 (27.7)
7 (14.9)
4.9 (3.4)

0.15
<0.0001
0.09
1.0

<0.0001
<0.0001
0.31
0.20

0.11
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LT (n=49)

LSBT (n=47)

p-value

17 (36.2)
0.2 (0.1)

0.05
0.34

Maintenance steroids at the time of biopsy, c n (%)
9 (18.4)
Steroids dose (mg/kg/d), median (IQR)
0.2 (0.3)
Serum-based fibrosis markers at the time of liver biopsy

AST/ALT ratio, median (IQR)
0.8 (0.5)
0.9 (0.7)
0.77
AST-to-platelet ratio index (APRI), median (IQR)
1.6 (2.6)
0.7 (2.3)
0.02
FIB4 score, median (IQR)
0.3 (0.6)
0.2 (0.3)
0.16
a History of PN after transplant was documented if the patient received PN  30 days
immediately post-transplant, or if PN was later restarted and continued for  30 days.
b Other included sirolimus, everolimus, or mycophenolate mofetil.
c Most LSBT patients were maintained on low-dose steroids after transplant as per our protocol.
Others remained on steroids for various reasons, such as history of rejection, autoimmune
hemolytic anemia, ongoing treatment for post-transplant lymphoproliferative disorder, or de
novo autoimmune hepatitis, etc.

Table 2 presents post-transplant complications by type of transplant. Acute liver
rejection was more frequently seen in LT than in LSBT children (61.2% vs. 14.9%,
p<0.0001), whereas PTLD was more prevalent in LSBT than in LT patients (12.8% vs.
2.0%, respectively, p=0.06). Additionally, 12.2% of LT children developed biliary
complications, versus 0% in the LSBT group (p=0.03).
Table 2. Post-transplant complications by type of transplant
LT (n=49)

LSBT (n=47)

p-value

30 (61.2)

7 (14.9)

<0.0001

Chronic liver rejection

4 (8.2)

4 (8.5)

1.0

PTLD in liver

1 (2.0)

6 (12.8)

0.06

Biliary complications

6 (12.2)

0 (0.0)

0.03

Vascular complication

6 (12.2)

2 (4.3)

0.27

Viral hepatitis

3 (6.1)

2 (4.3)

1.0

Acute intestinal rejection

n/a

17 (36.2)

n/a

Chronic intestinal rejection

n/a

6 (12.8)

n/a

0 (0.0)

15 (31.9)

<0.0001

Liver complications, n (%)
Acute liver rejection

Intestinal complications, n (%)

PTLD in intestine
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Prevalence of hepatic graft fibrosis
Of the 96 patients included, there were 14 liver explants and 13 liver autopsies. Most
patients had a donor liver biopsy at the time of transplant, and the majority were
normal (Table 3). Hepatic graft fibrosis was found in 81.6% of LT children after a median
time of 2.5 years post-transplant, compared to 70.2% in LSBT children after a median
time of 2.6 years (p=0.19). However, the majority of the patients had mild fibrosis, and
significant graft fibrosis (F2) was found in 36.7% of LT vs. 25.5% of LSBT children
(p=0.24). As shown in Figure 3, there was no statistically significant difference in the
probability of developing hepatic graft fibrosis over time between the two groups (logrank test, p=0.62).
Of note, at the time of liver biopsy, 75.5% of LT patients and 61.7% of LSBT
children had concurrent inflammation, and 9 (18.4%) LT and 2 (4.3%) LSBT children had
concurrent acute cellular rejection of the liver. Among the patients with advanced
hepatic graft fibrosis, 6 out of 9 LT children eventually received a repeat transplant, of
whom 3 with short-bowel syndrome received a secondary LSBT. In the LSBT group, 5 out
of 8 patients with advanced hepatic graft fibrosis underwent a repeat LSBT, but the
indication for re-transplant in these patients was primarily due to concurrent small
bowel graft failure rather than advanced liver fibrosis; one patient has been on the
waiting list for repeat LSBT due to chronic liver rejection and small bowel graft
dysfunction; two other patients died due to sepsis and multi-organ failure.
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Additionally, among 60 patients (35 LT and 25 LSBT) who had a repeat liver
biopsy after a median time of 18 months between the biopsies, the fibrosis stage was
decreased in 15% of the patients, whereas 45% showed a steady stage, and 40% showed
a progressive stage. Figure 4 and Figure 5 demonstrate the evolution of hepatic graft
fibrosis between the first and the last biopsies in LT vs. LSBT children. Of note, there was
no significant correlation between the presence of inflammation on the first biopsy and
the fibrosis stage on the last biopsy in both groups.

Figure 3. Cumulative probability of developing hepatic graft fibrosis in LT versus LSBT
children
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Table 3. Post-transplant hepatic fibrosis by type of transplant

Normal donor biopsy, n (%)
Time to liver biopsy (years), median (IQR)

LT (n=49)

LSBT (n=47)

p-value

32/37 (86.5)

40/46 (87.0)

1.00

2.5 (3.9)

2.6 (5.0)

0.80

Fibrosis stage, n (%)

0.54

No fibrosis (F0)

9 (18.4)

14 (29.8)

Stage 1 (F1)

22 (44.9)

21 (44.7)

Stage 2 (F2)

9 (18.4)

4 (8.5)

Stage 3 (F3)

7 (14.2)

6 (12.8)

Stage 4 (F4, cirrhosis)

2 (4.1)

2 (4.2)

Inflammation at the time of biopsy, n (%)

37 (75.5)

29 (61.7)

0.14

Acute liver rejection at the time of biopsy, n (%)

9 (18.4)

2 (4.3)

0.03

Figure 4. Evolution of hepatic graft fibrosis in LT children after a median time of 18
months between the first and the last biopsies
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Figure 5. Evolution of hepatic graft fibrosis in LSBT children after a median time of 18
months between the first and the last biopsies.

Risk factors associated with significant hepatic graft fibrosis
Table 4 summarizes univariate analyses of potential risk factors for significant hepatic
graft fibrosis (F2). In LT children, potential predictors were a history of post-transplant
PN use and chronic liver rejection, whereas in the LSBT group, the only potential
predictor was the AST/ALT ratio. For multivariate analyses, since the covariates donorto-recipient age ratio, CIT, history of acute liver rejection, and biliary complications were
significantly different between LT and LSBT groups and/or given their clinical relevance,
the following potential predictors were entered into a Cox proportional hazards
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regression model in the LT group: donor-to-recipient age ratio (continuous), CIT
(continuous), history of post-transplant PN use (yes vs. no), history of acute liver
rejection (yes vs. no), chronic liver rejection (yes vs. no), and biliary complications (yes
vs. no). In the LSBT group, the covariate AST/ALT ratio (continuous) was entered instead
of biliary complications as none of the LSBT children had biliary complications, and
AST/ALT ratio was found to be a significant predictor on univariate analysis in this group.
As shown in Table 5, on multiple regression analyses, having a history of post-transplant
biliary complications was an independent predictor for significant graft fibrosis in LT
children (adjusted hazard ratio: 4.47, 95% CI: 1.13-17.65, p=0.03), whereas donor-torecipient age ratio and CIT had a trend to be associated with significant graft fibrosis. In
LSBT children, AST/ALT ratio was consistently found to be associated with significant
graft fibrosis, and each unit increase in AST/ALT ratio was associated with a 60%
increase in the hazard of having significant graft fibrosis (95% CI: 1.07-2.40, p=0.02)
(Table 5).
Post-transplant antibodies and significant hepatic graft fibrosis
Annual monitoring of post-transplant antibodies (i.e., autoimmune antibodies and DSA)
was not routinely performed in our center. Among the patients who had DSA tested, 3/4
LT and 4/10 LSBT children were positive for class I and/or class II DSA; and 1/3 LT and
2/4 LSBT patients with DSA positivity had significant graft fibrosis on liver biopsy (Table
4). Among the patients who had autoimmune antibodies available, 8/17 LT children and
10/13 LSBT children were positive for at least one of the autoimmune markers tested.
As shown in Table 4, one of these 8 LT children and 4 of these 10 LSBT children had
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significant graft fibrosis. Of note, among those with positive autoimmune antibodies, 6
patients (3 LT and 3 LSBT) fulfilled the diagnostic criteria for de novo autoimmune
hepatitis, which included elevated liver enzymes, autoantibody positivity, raised
immunoglobulin level, and histology consistent with autoimmune hepatitis.

Table 4. Results of univariate analyses of potential predictors for significant hepatic graft fibrosis in LT versus LSBT children
LT (n=49)

LSBT (n=47)

No/mild
fibrosis
(F0-F1)
(n=31)

Significant
fibrosis
(F2-F4)
(n=18)

p-value

No/mild
fibrosis
(F0-F1)
(n=35)

Significant
fibrosis
(F2-F4)
(n=12)

p-value

1.3 (4.0)
12.8 (6.0)
14 (45.2)

0.8 (0.5)
12.8 (5.2)
9 (50.0)

0.08
0.66
0.74
0.67

1.3 (1.9)
11.1 (9.5)
24 (68.6)

1.3 (0.5)
9.0 (8.2)
7 (58.3)

0.65
0.26
0.73
0.81

17 (54.8)
14 (45.2)

11 (61.1)
7 (38.9)

16 (45.7)
19 (54.3)

5 (41.7)
7 (58.3)

27/29 (93.1)
2/29 (6.9)
1.9 (14.4)
7.5 (3.6)
16 (51.6)
5 (16.1)
5 (16.1)
0 (0.0)

15/16 (93.8)
1/16 (6.3)
7.7 (13.2)
7.8 (1.8)
12 (66.7)
7 (38.9)
7 (38.9)
3 (16.7)

31 (91.2)
3 (8.8)
0.3 (0.3)
8.3 (2.3)
15 (42.9)
28 (80.0)
26 (74.3)
3 (8.6)

12 (100.0)
0 (0.0)
0.5 (0.9)
8.3 (1.9)
5 (41.7)
10 (83.3)
9 (75.0)
3 (25.0)

20 (64.5)
8 (25.8)
3 (9.7)
4.0 (3.1)

16 (88.9)
2 (11.1)
0 (0.0)
4.4 (3.6)

0.96

21 (60.0)
9 (25.7)
5 (14.3)
5.5 (3.3)

6 (50.0)
4 (33.3)
2 (16.7)
4.8 (3.8)

0.34

8 (25.8)

1 (5.6)

0.13

12 (34.3)

5 (41.7)

0.65

Clinical characteristics
Age at transplant (years), median (IQR)
Follow-up after transplant (years), median (IQR)
Female, n (%)
Ethnicity, n (%)
White
Other
ABO compatibility, n (%)
Identical
Compatible
Donor-to-recipient age ratio, median (IQR)
Cold ischemia time (hours), median (IQR)
Positive recipient cytomegalovirus status, n (%)
Post-transplant parenteral nutrition, a n (%)
Prolonged  30 days post-transplant
Restarted and continued  30 days
Immunosuppression, n (%)
Maintenance immunosuppression
Tacrolimus only
Tacrolimus and other b
Non-tacrolimus
Immunosuppressant level (ng/mL) at the time of liver
biopsy, median (IQR)
Maintenance steroids at the time of liver biopsy
Post-transplant liver complications, n (%)

1.0

0.16
0.84
0.30
0.07
0.07
0.04

0.56

0.17

0.24
0.96
0.94
1.0
1.0
0.16
0.90
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LT (n=49)

Acute liver rejection
Chronic liver rejection
PTLD in liver
Biliary complications
Vascular complications
Viral hepatitis
Histologic characteristics, n (%)
Abnormal donor liver biopsy
Time to liver biopsy (years), median (IQR)
Concurrent inflammation at the time of biopsy
Concurrent acute liver rejection at the time of biopsy
Post-transplant antibody positivity, n (%)

LSBT (n=47)

No/mild
fibrosis
(F0-F1)
(n=31)
20 (64.5)
0 (0.0)
1 (3.2)
3 (9.7)
3 (9.7)
2 (6.5)

Significant
fibrosis
(F2-F4)
(n=18)
10 (55.6)
4 (22.2)
0 (0.0)
3 (16.7)
3 (16.7)
1 (5.6)

p-value

4/24 (16.7)
2.0 (3.9)
22 (71.0)
7 (22.6)

Preformed antibodies
3/3
Donor-specific antibodies c
2/3
d
Autoimmune markers
7/8
Serum-based fibrosis markers at the time of liver biopsy, median (IQR)

Significant
fibrosis
(F2-F4)
(n=12)
2 (16.7)
2 (16.7)
1 (8.3)
0 (0)
2 (16.7)
0 (0.0)

p-value

0.53
0.01
1.0
0.66
0.66
1.0

No/mild
fibrosis
(F0-F1)
(n=35)
5 (14.3)
2 (5.7)
5 (14.3)
0 (0)
0 (0.0)
2 (5.7)

1/13 (7.7)
2.8 (4.0)
15 (83.3)
2 (11.1)

0.64
0.49
0.49
0.45

5/35 (14.3)
2.4 (5.1)
21 (60.0)
2 (5.7)

1/11 (9.1)
3.1 (4.5)
8 (66.7)
0 (0.0)

1.0
0.57
0.74
1.0

0/3
1/3
1/8

0.14
1.0
1.0

3/4
2/4
6/10

1/4
2/4
4/10

1.0
1.0
0.56

1.0
0.27
1.0
n/a
0.06
1.0

AST/ALT ratio
0.8 (0.6)
0.9 (0.5)
0.95
0.8 (0.4)
1.6 (1.6)
0.01
APRI
1.4 (3.2)
2.0 (2.0)
0.19
0.7 (1.8)
2.5 (8.8)
0.10
FIB4
0.4 (0.7)
0.2 (0.6)
0.97
0.1 (0.3)
0.5 (1.6)
0.10
a History of post-transplant parenteral nutrition was documented if the patient received parenteral nutrition  30 days immediately post-transplant, or if
parenteral nutrition was later restarted and continued for  30 days.
b Other included sirolimus, everolimus, or mycophenolate mofetil.
c Donor-specific antibodies were determined using a single antigen bead assay. The cutoff for reporting DSA is 1,000 MFI.
d Among patients with positive autoimmune markers, 3 LT and 3 LSBT children fulfilled the diagnostic criteria for de novo autoimmune hepatitis. Of these, 1
LT and 2 LSBT patients had significant fibrosis on liver biopsy.

Table 5. Results of multivariate analyses of potential predictors for significant hepatic
graft fibrosis in LT versus LSBT children
Variables

Adjusted hazard ratio (95% CI)

p-value

History of biliary complications (yes vs. no)

4.47 (1.13 - 17.65)

0.03

Donor-to-recipient age ratio

1.03 (1.00 - 1.07)

0.08

Cold ischemia time (hour)

1.27 (0.98 - 1.65)

0.08

1.60 (1.07 - 2.40)

0.02

LT group

LSBT group
AST/ALT ratio

Discussion
Hepatic graft fibrosis has been reported as early as 12 months following pediatric LT in
serial protocol biopsies,3,7 but little is known about its prevalence following pediatric
LSBT. To our knowledge, the present study was the first to report the prevalence of
hepatic graft fibrosis in LSBT children and compare it with that in LT children. Our
findings showed that LSBT children could also develop hepatic graft fibrosis over time;
its prevalence did not significantly differ from that in LT patients (70.2% vs. 81.6%,
p=0.19). Additionally, significant graft fibrosis (F2) was found in 25.5% of LSBT versus
36.7% of LT children. Moreover, hepatic graft fibrosis appeared to be dynamic over
time, and the fibrosis stage could decrease with time, especially in patients with mild
fibrosis. Hence, it is important to recognize hepatic graft fibrosis at an early stage and
identify its predisposing factors in order to develop strategies to minimize the risks and
halt its progression at a stage where the fibrosis might not yet be clinically apparent but
has the potential for progression.
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Previous studies have investigated risk factors predicting hepatic fibrosis in LT
children. In one study,4 prolonged CIT, young age at the time of transplant, high donorrecipient age ratio, and the use of partial grafts were found to be significant predictors
associated with hepatic fibrosis in LT children. In another study, 9 biliary complications
and positive recipient CMV status were found to be significant factors, in addition to a
prolonged CIT, whereas acute liver rejection was found to be a negative predictor for
hepatic graft fibrosis. Our multiple regression analyses have demonstrated that having a
history of post-transplant biliary complications was an independent predictor for
significant graft fibrosis in LT children. Increasing donor-to-recipient age ratio and
increasing allograft CIT also appeared to be associated with significant graft fibrosis in LT
children, although this trend was not statistically significant due to the small sample
size. Prolonged CIT might have an impact on the development of portal fibrosis because
the biliary tract appears to be more susceptible to a prolonged CIT than hepatic
parenchyma, which might result in ischemic injury and subsequent fibrosis; 18,19 and the
relationship between biliary complications and portal fibrosis, with subsequent biliary
cirrhosis, has been well described.9,20 Additionally, despite contradictory results in
published literature, CIT has been described as a relevant risk factor for the
development of post-transplant ischemic-type biliary complications in several adult
studies.21-23 In a pediatric study,19 CIT and donor age were also reported to be significant
risk factors for the development of ischemic-type biliary lesions following LT. Published
studies in adults also demonstrated an association between increasing donor age,
prolonged ischemia time, and the risk of graft failure after LT.20,24-27 Unlike the LT group,
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AST/ALT ratio was found to be the only significant predictor associated with significant
graft fibrosis in LSBT children after adjusting for other covariates. The fact that the
donor-to-recipient age ratio did not appear to be associated with significant graft
fibrosis in LSBT children could be explained by a significantly lower donor-to-recipient
age ratio in LSBT than in LT children (0.4 vs. 3.5, respectively). Furthermore, in contrast
to a previous study that demonstrated a negative correlation between acute liver
rejection and hepatic graft fibrosis in LT children,9 our multivariate analyses did not
support this finding. However, there was a significantly lower rate of acute liver
rejection in LSBT than in LT children on univariate analyses, which could be explained by
relatively higher levels of immunosuppression that these LSBT children often require
after transplant.
The role of post-transplant DSA in the development of hepatic graft fibrosis
following LT has been proposed,7,28 and post-transplant autoimmune antibody
formation has also been reported to be an independent predictor of chronic allograft
hepatitis that could lead to progressive fibrosis in pediatric LT recipients.3 The
prevalence of autoimmune antibodies and de novo DSA following pediatric LT has been
reported in previous pediatric studies, ranging between 40-60% and 50-60% by 5-10
years after transplant, respectively.3,29-31 The prevalence of these antibodies in LSBT
children and their clinical impact on long-term graft outcomes, however, have not been
well described, which might reflect a much smaller number of pediatric intestinal
transplants and combined LSBT performed worldwide. Theoretically, patients with
intestinal transplants might be more likely to develop de novo DSA after transplant
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because the small bowel graft is a highly immunogenic organ with enormous lymphoid
tissue. On the other hand, the immunologic benefit of a liver-inclusive graft has been
proposed, emphasizing the ability of the liver graft to eliminate and neutralize human
leukocyte antigen antibodies, and hence, help increase the clearance of preformed DSA
and prevent the formation of de novo DSA.32 Accordingly, several adult studies and
small pediatric series have reported a lower prevalence of de novo DSA in LSBT patients,
ranging between 18% and 33%.32-36 These studies have described an association
between de novo DSA positivity and the occurrence of acute intestinal rejection, chronic
intestinal rejection, and inferior graft outcomes in LSBT patients. However, none has
specifically examined the relationship between de novo DSA and the development of
hepatic graft fibrosis in these LSBT recipients. In the present study, since the posttransplant antibodies were performed in our center only when clinically indicated, the
number of patients who had the post-transplant antibody testing was insufficient to be
included in a Cox regression model to examine the association between these
antibodies and hepatic graft fibrosis. Whether these post-transplant antibodies could be
predisposing factors for hepatic graft fibrosis in LSBT children merits further
investigation in a larger scale, multicenter study.
Compared with LT children, patients with LSBT generally require prolonged PN
during the post-operative course or later need reintroduction of PN due to several
reasons, such as feeding intolerance, temporarily withholding enteral feeds due to acute
intestinal rejection or small bowel graft failure, all of which can result in PN-related liver
injury. Nevertheless, in the present study, post-transplant PN use did not appear to be
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significantly associated with significant hepatic graft fibrosis in LSBT children. In the LT
group, all 12 LT children who had prolonged PN immediately post-transplant had
intestinal failure and underwent primary LT for intestinal failure-associated liver disease;
three of these later required reintroduction of PN due to feeding intolerance or growth
failure, and subsequently underwent a secondary LSBT. In this group, although posttransplant PN use appeared to be associated with significant hepatic graft fibrosis in the
univariate analysis, it did not reach statistical significance in the multivariate analysis.
Limitations of the present study were mainly related to its retrospective nature.
Although the effort was made to retrieve available biopsy specimens for confirmation of
fibrosis stage by a single, experienced transplant pathologist to avoid interobserver
error, approximately one-third of the biopsy specimens could not be retrieved and
reviewed. Hence, there might be discordance in fibrosis staging among pathologists.
Additionally, because the liver biopsy was performed in our center only when clinically
indicated, the present study might be subject to patient selection bias, which could be
overcome by a prospective study of protocol biopsies. Although serum-based fibrosis
markers, such as AST/ALT ratio, APRI, or FIB4, have recently been investigated for
predicting hepatic graft fibrosis in LT, in the present study, only the AST/ALT ratio was
found to be significant in the univariate analysis and thus was entered into the
multivariate analysis in the LSBT group, where it was consistently found to be a
significant predictor for significant hepatic graft fibrosis. However, this finding warrants
further validation in future studies of protocol liver biopsies because the liver biopsy
was performed only for clinical indications in the present cohort, at the time when all
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patients had elevated liver enzymes that might or might not be related to hepatic
fibrosis. The biomarkers APRI and FIB4 were not found to be associated with significant
hepatic graft fibrosis in the univariate analysis, and therefore, were not entered into the
Cox regression model. Moreover, the reliability of these biomarkers in the pediatric LT
population has been questioned because these biomarkers are calculated based on AST,
ALT, platelet count, and patient's age, which might be affected by conditions other than
hepatic graft fibrosis, such as persistent thrombocytopenia secondary to splenomegaly
in the setting of post-transplant portal vein obstruction, thrombocytosis in LSBT children
who often have concurrent splenectomy at the time of transplant, or the fact that the
patient's age does not correspond to the hepatic graft's age (i.e., older graft age in LT vs.
younger graft age in LSBT children). Consequently, APRI or FIB4 might not accurately
predict the presence of hepatic graft fibrosis in these pediatric transplant recipients.
Furthermore, since this was an observational study, the reported association between
biliary complications and significant hepatic graft fibrosis in LT children, although
consistent with published literature, might not represent a causal relationship and
would need to be validated in future prognostic studies.

Conclusions
The present study has shown that the prevalence of hepatic graft fibrosis in LSBT
children did not significantly differ from that in LT children, but the predictors for
fibrosis may differ. A history of biliary complications was found consistently to be an
independent predictor for significant graft fibrosis in LT children, whereas the AST/ALT
ratio was found to predict significant hepatic graft fibrosis in LSBT children. Early

27

diagnosis and aggressive treatment of biliary complications as well as strategies to
optimize graft quality (i.e., avoidance of prolonged CIT) might help reduce the
prevalence of significant graft fibrosis in LT children. Future studies should investigate
the roles of post-transplant autoimmune antibodies and DSA in the development and
progression of hepatic graft fibrosis, especially in LSBT children.
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Chapter 2: Non-Invasive Methods for Evaluation of Hepatic Graft
Fibrosis
Background
Hepatic graft fibrosis is a common histologic finding in long-term pediatric LT
survivors.3,7,8 Liver biopsy is the gold standard for fibrosis assessment and staging, but it
is invasive, requires general anesthesia in children, and has potential complications.13
Therefore, non-invasive methods, such as serum-based fibrosis markers and
elastography, have been increasingly investigated for assessing liver fibrosis in children.
Serum-based fibrosis markers can be classified into two categories: (1) direct markers
investigating the fibrosis process (i.e., enhanced liver fibrosis test [ELF]), and (2) indirect
markers assessing hepatic synthetic function (i.e., AST/ALT ratio, FIB4, APRI, and
FibroTest) (Table 6).37 While direct biomarkers reflect extracellular matrix turnover and
their serum levels may serve as indicators of fibrosis severity, they are neither organspecific nor widely available. On the other hand, indirect biomarkers reflect alterations
of hepatic synthetic function and help assess the severity and prognosis of liver disease.
Elastography examines the intrinsic property of the liver tissue by measuring
liver stiffness (LS), with elevated stiffness often associated with liver fibrosis or cirrhosis.
Elastography techniques can be ultrasound-based or magnetic resonance imagingbased. Ultrasound-based elastography includes vibration-controlled transient
elastography (TE), point shear wave elastography (SWE), also known as acoustic
radiation force impulse (ARFI), and 2-dimensional SWE (2D-SWE). Systematic review and
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meta-analysis examining the diagnostic performance of these non-invasive tests,
specifically elastography, for assessing liver fibrosis in the non-transplant setting have
been reported in adults with chronic liver disease,38-41 and recently in children with
various types of chronic liver disease.42 However, little is known about the diagnostic
accuracy of elastography and serum markers in predicting hepatic graft fibrosis in the
setting of pediatric LT. A recent meta-analysis43 has compared the diagnostic accuracy of
TE and serum fibrosis markers, such as APRI and FIB4, with liver biopsy in diagnosing
recurrent hepatic fibrosis after LT, but data included mixed results of both children and
adults, with highly heterogeneous study populations and highly different primary liver
pathologies. This scoping review aimed to review the published literature on the
diagnostic accuracy of elastography and selected serum-based fibrosis markers for
assessing hepatic graft fibrosis, exclusively in pediatric LT recipients.
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Table 6. Selected serum-based fibrosis markers for assessment of hepatic fibrosis
Components

Equation

Indirect biomarkers
AST/ALT ratio

AST, ALT

AST⁄ALT

FIB4

Platelet, AST, ALT, age

Age (years) x AST
Platelet count (109/L) x √ALT

APRI

Platelet, AST

AST/AST (upper normal value)
Platelet count (109/L)

FibroTest

Age, sex, alpha 2-macroglobulin,

Commercial panel

x 100

alpha 2-globulin, gamma-globulin,
apolipoprotein A1, GGT, total
bilirubin
Direct biomarkers
ELF

Hyaluronic acid, tissue inhibitor of

Commercial panel

metalloproteinase-1, type III collagen
APRI, AST-to-platelet ratio index; ELF, enhanced liver fibrosis test; FIB4, fibrosis-4 score

Methods
We conducted a scoping review according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRIMA-ScR)
guidelines.44
Literature search
We performed a systematic search of published literature in PubMed (MEDLINE),
EMBASE, SCOPUS, and Cochrane Library between 2002 (when TE was first introduced)
and 10/2019. The following MeSH terms and their combinations were searched in
[Title/Abstract]: liver fibrosis, hepatic fibrosis, early fibrosis, advanced liver fibrosis,
significant liver fibrosis, liver cirrhosis, liver transplant, hepatic transplant, liver
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transplantation, post-transplant, elasticity imaging technique, liver elastography,
transient elastography, Fibroscan, shear-wave elastography, ARFI, magnetic resonance
elastography, non-invasive fibrosis markers, serum fibrosis markers, AST/ALT ratio, APRI,
FIB4, FibroTest, ELF. Additionally, to identify grey literature, we searched Google Scholar
using a search strategy for conference proceedings and publications as well as searched
through the websites and conference abstract books of the major gastroenterology and
hepatology societies (i.e., American Association for the Study of the Liver Diseases,
European Association for the Study of the Liver, Asian Pacific Association for the Study
of the Liver, North American Society for Pediatric Gastroenterology, Hepatology and
Nutrition, European Society for Paediatric Gastroenterology, Hepatology and Nutrition,
and International Pediatric Transplant Association), and manually reviewed the
reference lists of the included studies.
Selection criteria
Studies were included in the review if they met the following criteria: the study was
published in the English language; the study used at least one of the elastography
techniques, such as TE, ARFI, SWE, or magnetic resonance elastography, to assess liver
graft fibrosis; the study used at least one of the serum-based fibrosis markers, such as
AST/ALT ratio, APRI, FIB4, FibroTest, or ELF, to assess liver graft fibrosis; the study
enrolled pediatric patients (aged 18 years or younger), or a subgroup of pediatric
patients who had received a liver transplant; the study used liver biopsy as the
reference test to stage liver fibrosis according to one of the staging systems: METAVIR,
Batts-Ludwig, or Ishak; the study provided the diagnostic performance or diagnostic
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accuracy of the test, reported as the area under the receiver operating characteristic
curve (AUROC) and/or sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV). Of note, a receiver operating characteristic (ROC) curve depicts a
trade-off between sensitivity and specificity (Figure 6). The ROC curve plots the true
positive rate (i.e., sensitivity) against the false positive rate (i.e., 1-specificity) for
different cutoff points of a test. The closer the curve follows the upper-left-hand border
and the larger the area under the curve, the more accurate the test is. The AUROC
depicts a trade-off between sensitivity and specificity: when the threshold decreases,
the sensitivity increases and the specificity decreases, and vice versa. Hence, when the
sensitivity increases, the false positive rate also increases, and vice versa. High
sensitivity is more helpful for screening tests, whereas high specificity is more helpful for
diagnostic tests. The AUROC describes the diagnostic capacity of a test: an AUROC of
0.9-1 represents an excellent test, an AUROC of 0.8-0.9 represents a good test, an
AUROC of 0.7-0.8 represents a fair test, an AUROC of 0.6-0.7 represents a poor test,
whereas an AUROC of 0.5 represents a worthless test.
We included all eligible studies, whether they were available in abstract or fulltext, as the aim of this scoping review was to examine the extent of the literature on the
current status of using elastography and serum-based fibrosis markers in pediatric LT,
unlike systematic review or meta-analyses where exclusion is based on critical appraisal
of methodological quality. If a conference abstract was subsequently published as a fulllength article or presented at different meetings (with the same data or increased
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number of patients), only the full-length article or the most recent abstract was
included.

Figure 6. Receiver operating characteristic (ROC) curve and the area under the receiver
operating characteristic curve (AUROC)
Literature analysis and synthesis
After identification of the eligible studies, the authors abstracted the key study
characteristics, including study design, number of patients, patient characteristics, age
range, interventions, histological fibrosis staging, LS cutoff values or serum marker
cutoff values for various fibrosis stages, technical failures of elastography techniques if
reported. If there were any discrepancies, a final consensus was obtained after the
discussion.
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Data and results of the included studies were summarized according to various
elastography techniques and serum-based fibrosis markers. For different fibrosis stages,
scores from Ishak system (F0-6) were transformed to METAVIR system (F0-4), with Ishak
F0 assigned to METAVIR F0, Ishak F1 assigned to METAVIR F1, Ishak F2-3 assigned to
METAVIR F2, Ishak F4-5 assigned to METAVIR F3, and Ishak F6 assigned to METAVIR F4;
scores from Batts-Ludwig system (F0-4) were converted to the same score as in
METAVIR system (F0-4).

Results
The literature search and study selection are summarized in Figure 7. Among 176
records identified using the search criteria, 8 studies met the inclusion criteria, of which
5 were full-text articles, and 3 were available only in abstract form. Studies were
excluded because they were not relevant to the evaluation of hepatic graft fibrosis after
pediatric LT, or there was no data reported for the diagnostic accuracy of the studied
non-invasive test(s). The final data set included 6 studies examining TE, 45-50 one study
investigating ARFI,51 and 5 studies examining various types of serum-based fibrosis
markers48-52 (Table 7).
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Figure 7. Flow diagram of the search strategy and study selection

Characteristics of the included studies
As shown in Table 7, a total of 8 studies were included,45-52 of which 6 were prospective.
These studies included a total of 274 LT children; in 2 studies,47,48 pediatric LT recipients
were a subgroup of children undergoing non-invasive evaluation of hepatic fibrosis for
various types of chronic liver disease. In 7 studies,45,47-52 the median time from
transplant to liver biopsy reportedly ranged from 1.4 to 13.72 years. In 5 studies, 47,49-52
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the reported prevalence of hepatic graft fibrosis (F1) ranged from 50% to 100%. The
majority of the studies had the non-invasive test(s) performed on the same day as a liver
biopsy.
Diagnostic performance of transient elastography
A total of 195 pediatric LT recipients were included in the 6 TE studies (Table 8). The
prevalence of hepatic graft fibrosis was reported in 3 studies, 47,49,50 and ranged from
53% to 100%. In 3 studies,45,46,48 the AUROC for the presence of hepatic graft fibrosis
(F1) ranged from 0.82 to 0.92; the optimal LS cutoff value for the discrimination of
hepatic graft fibrosis ranged from 7.05 to 8 kilopascals (kPa) (Table 8). Moreover, as
reported in 4 studies,47-50 TE was able to distinguish children with significant hepatic
graft fibrosis (F2) from those with no/mild hepatic graft fibrosis (<F2) with a fair to
excellent AUROC, ranging from 0.71 to 0.98; the optimal cut-point for predicting
significant hepatic graft fibrosis reportedly ranged from 5.6 to 11.2 kPa, with a
sensitivity and a specificity ranging from 60% to 100% and 78% to 95.8%, respectively
(Table 8). Two studies47,48 reported a good to excellent AUROC for predicting advanced
hepatic graft fibrosis (F3), ranging from 0.83 to 1.
Three studies46,48,49 reported the effect of graft type on LS. Overall, TE has shown
to be feasible in both whole liver and partial liver grafts using the proper TE
technique.46,48 Although LS value appeared to be slightly higher in left split grafts than
full-size grafts (Table 7),46,48 data were insufficient to propose specific LS cut-points for
these graft types. Additionally, LS value has been reported to be higher in LT children
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who had received a deceased donor graft (compared to living-related graft), in those
with a history of cholangitis/biliary complications or hepatic venous outflow obstruction,
and in those who received an mTOR (mammalian target of rapamycin) inhibitor-based
immunosuppression;48 LS value was lower in those with concurrent acute liver
rejection.48
Diagnostic performance of ARFI
Only one study,51 with 30 LT children, examined the diagnostic performance of ARFI,
which reported a fair AUROC of 0.76 for predicting significant hepatic graft fibrosis, with
a sensitivity of 83% and a specificity of 71% (Table 8). However, the combination of ARFI
and AST/ALT ratio improved the AUROC to 0.83.
Diagnostic performance of selected serum-based fibrosis markers
A total of 220 LT children were included in 5 studies examining the diagnostic accuracy
of serum-based fibrosis markers. The prevalence of hepatic graft fibrosis was reported
in 4 studies,49-52 ranging from 50% to 82% (Table 7).
AST/ALT ratio. Only one study51 with 30 LT children examined the diagnostic accuracy of
the AST/ALT ratio for predicting significant hepatic graft fibrosis (F2); it showed a poor
AUROC of 0.69. However, the combination of ARFI elastography and AST/ALT ratio
showed a good AUROC of 0.83 for distinguishing children with significant hepatic graft
fibrosis from those with no/mild hepatic graft fibrosis (p=0.013).
AST-to-platelet ratio index (APRI). Four studies49-52 examined the diagnostic accuracy of
APRI (Table 9). In two studies,49,50 APRI failed to distinguish patients with significant
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hepatic graft fibrosis (F2) from those with no/mild fibrosis (AUROC ranged from 0.530.59). In contrast, in the other two studies,51,52 APRI showed a fair AUROC (0.74) for
predicting significant hepatic graft fibrosis. Of note, the combination of APRI with ARFI
elastography did not improve its diagnostic performance.51
Enhanced liver fibrosis test (ELF) and FibroTest. One study48 examined the use of
patented panels of serum-based fibrosis markers, such as ELF and FibroTest, in LT
children, compared to healthy children. The cutoffs for these biomarkers were based on
the manufacturers' references. The authors reported no significant correlation between
FibroTest and ELF values and hepatic fibrosis staging confirmed by liver biopsy, and
standard values for normal or various stages of hepatic graft fibrosis could not be
transferred from non-transplant children. Moreover, the AUROC calculation for both
FibroTest and ELF did not show any diagnostic value, and neither FibroTest nor ELF were
able to discriminate between different stages of hepatic graft fibrosis. 48

Table 7. Characteristics of the included studies
Study

Noninvasive
test

Study design

Number of
patients/Patient
characteristics

Costa46

TE

Prospective

n=11
• All had biopsy for
clinical indication
• Whole graft 4, left
split graft 7

Lee49

TE
APRI

NR

Vinciguerra50

TE
APRI

Prospective

Median
(IQR) age at
biopsy
(year)

Median
(IQR) time
from biopsy
to the test

Fibrosis
assessment

NR

Median
(IQR)/Mean
(SD) time from
transplant to
biopsy (year)
NR

Same day,
except 1
within one
month

NR

n=83
• All had biopsy for
clinical indication
• Whole graft 40%,
technical variant
graft 54%, multivisceral 6%
• Biliary atresia
40%, malignancy
17%, metabolic
disease 14%

NR

5 years

65 days

METAVIR
F0 47%
F1 29%
F2 18%
F3 5%
F4 1%

n=36
• All had biopsy for
clinical indication
• Full-size graft
44%, reduced-size
45%, split graft
31%
• Biliary atresia
61%, autoimmune

7.5 (3.9915.32)

3.02 (1.53-5.5)

-0.012
month
(-0.521 to
0.268)

METAVIR
F0 25%
F1 42%
F2 25%
F3 3%
F4 5%

Median
(IQR)/Mean
(SD) value for
the test

Comments

Mean LSM
(kPa):
Whole graft
5.8 (1.74)
Split graft 6.9
(3.50)
<F2 vs. F2:
Median LSM
(kPa):
4.9 (3.8-6.5)
vs. 7.5 (4.613.6),
p=0.005
Median APRI:
0.45 (0.31–
0.62) vs. 0.44
(0.34–1.05),
p=0.72
• Median LSM
(kPa): Fullsize graft
4.55 (3.855.4);
reduced-size
5.6 (3.8-6.8);
split graft
4.8 (4.6-6.8).

• All patients
had
IQR/median
value < 30%
• 8 patients had
acute liver
rejection
within 90 days
of TE
• Similar
correlation
with biopsy
among
technical
variant and
whole grafts
• Median TE
success rate
93%
• IQR of 10 valid
measurements
14.95%
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Study

Noninvasive
test

Study design

Number of
patients/Patient
characteristics

Median
(IQR) age at
biopsy
(year)

Median
(IQR)/Mean
(SD) time from
transplant to
biopsy (year)

Median
(IQR) time
from biopsy
to the test

Fibrosis
assessment

liver disease 11%,
malignancy 16%,
metabolic disease
3%, genetic liver
disease 6%, other
3%
• Post-transplant
complications
53%

Boldrini45

TE

Prospective

Goldschmidt48

TE
FibroTest
ELF

Prospective

n=23
n=36
• 26 had TE, 28 had
FibroTest, and 23
had ELF
• Biliary atresia
46.2%, acute liver
failure 6.8%,
autoimmune liver
disease 5.1%,
malignancy 5.1%,
metabolic disease
8.5%, cholestatic
liver disease
13.7%, other
14.6%

NR

13.72 (4.9)

NR

METAVIR

5.6

1.4

0.2 (0-5.8)
months

Ishak
Median
degree of
fibrosis 1.0
(0-6)

Median
(IQR)/Mean
(SD) value for
the test

Comments

• <F2 vs. F2:
Median LSM
(kPa):
4.55 (3.94.95) vs. 6.85
(5.25-9.0),
p=0.001
Median APRI:
0.34 (0.280.57) vs. 0.44
(0.27-0.78),
p=0.39
F1 cutoff
7.8kPa
Median LSM • 117 LT children
(kPa):
included, only
• F0-F2 vs. F336 had biopsy
F6: 8 (5.3for clinical
20.4) vs.
indication
24.5 (20.4• TE was
75), p<0.05
successful in
• F1 vs. F2:
88.5% full-size
7.2 (5.3grafts, 77.8%
20.4) vs. 12
right lobe
(7.9-19.8),
grafts, 26.2%
p<0.05
left split grafts
(improved to
• F2 vs. F3: 12
69% when
(7.9-19.8) vs.
performed in
20.6 (20.4-
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Study

Noninvasive
test

Study design

Number of
patients/Patient
characteristics

Median
(IQR) age at
biopsy
(year)

Median
(IQR)/Mean
(SD) time from
transplant to
biopsy (year)

Median
(IQR) time
from biopsy
to the test

Fibrosis
assessment

• Full-size 24.8%,
right split 7.7%,
left split 67.5%,
living-related graft
28.9%

Median
(IQR)/Mean
(SD) value for
the test
20.8),
p>0.05

Fitzpatrick47

TE

Prospective

n=16
• 11 had protocol
biopsy, 5 had
biopsy for
suspected graft
dysfunction
• Whole graft 4, left
lateral graft 12

11.8 (9.114.3)

10.2 (5.1-11.4)

same day

METAVIR
F1: 100%

Pinto51

ARFI
APRI
AST/ALT

Prospective

n=30
• 27 had protocol
biopsy, 3 had
biopsy for
suspected
rejection
• Biliary atresia
40%, metabolic
disease 46.7%,
malignancy 3.3%,
other 10%

11 (3-18)

6.8 (1-11)

ARFI: 1 day
before
biopsy
Blood tests:
same day

BattsLudwig
F0: 50%
F1: 30%
F2: 16.7%
F3: 3.3%
F4: 0%

Comments

midclavicular
line)
• Patients with
concurrent
acute liver
rejection had
lower LSM
Median LSM • 104 children
(kPa):
with various
F1: 6.2 (5.9liver diseases,
6.7)
of whom 16
F2: 10.4 (7.1were post26)
transplant
F3: 16.8 (9.5- • TE failed in 3
25)
patients with
F4: 29.1
left lateral
graft
F0-F1 vs. F2: • The effect of
Mean LSM
graft type on
(m/s):
ARFI value was
1.43 (0.40)
not evaluated
vs. 1.91
• The different
(0.48), p=0.05 types of
Mean APRI:
approach
0.58 (0.92)
(subxiphoid vs.
vs. 1.00
intercostal) in
(0.88),
ARFI data
p=0.065
acquisition
Mean
AST/ALT:
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Study

Noninvasive
test

Study design

Number of
patients/Patient
characteristics

Median
(IQR) age at
biopsy
(year)

Median
(IQR)/Mean
(SD) time from
transplant to
biopsy (year)

Median
(IQR) time
from biopsy
to the test

Fibrosis
assessment

Median
(IQR)/Mean
(SD) value for
the test

Comments

1.37 (0.65)
were not
vs. 0.94
compared
(0.10),
p=0.162
D'Souza52
APRI
Retrospective n=39
12.52
10.39 (9.93same day
Ishak
Median APRI:
(10.6811.69)
F0: 7; F1: 9
F1: 0.31 (0.2• All had protocol
14.36)
F2: 8; F3: 8
0.39)
biopsy
F4: 4; F5: 2
F2: 0.31
• Extrahepatic
F6: 1
(0.23-0.47)
biliary cirrhosis
F3: 0.51
22, progressive
(0.36-0.81)
familial
F4: 0.58
intrahepatic
(0.25-1.79)
cholestasis 4,
F5: 0.45 and
malignancy 3,
1.18
other 10
F6: 4.64
ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST-to-platelet ratio index; ARFI, acoustic radiation force impulse; AUROC, area under the
receiver operating characteristic curve; ELF, enhanced liver fibrosis test; IQR, interquartile range; LSM, liver stiffness measurement; NR, not reported; SD, standard
deviation; TE, transient elastography.
Note: Ishak vs. Batts-Ludwig/METAVIR fibrosis staging: F1 vs. F1, F2-3 vs. F2, F4-5 vs. F3, F6 vs. F4, respectively. Significant fibrosis was defined as Ishak F3 or
METAVIR F2.

Table 8. Summary of the studies examining the diagnostic performance of elastography for assessing hepatic graft fibrosis in LT
children
Study

F1

N

Sen
Cutoff (%)
Transient Elastography (TE), kPa

Spe
(%)

Costa46

11

Sen
(%)

Spe
(%)

PPV
(%)

NPV
(%)

AUROC

100

Lee49

83

6.5

60

78

46

86

0.71

Vinciguerra50

36

5.6

75

95.8

90

88.5

0.865

Boldrini45

23

7.8

87

75

86

67

0.82

Goldschmidt48

26a

7.2

78

50

78

50

0.68

9.3

90

81

75

93

15a

8

78

83

81

55

0.92

11.2

100

90

48

100

6.9

100

80

1.57

83

71

Fitzpatrick47

80

16

NPV
(%)

F3

Cutoff

7.05

PPV
(%)

F2
AUROC

Cutoff

Sen
(%)

Spe
(%)

PPV
(%)

NPV
(%)

AUROC

0.93

12.7

100

81

56

100

0.99

0.98

14.2

100

83

23

100

1

0.9

10.5

60

75

0.825

0.83

Acoustic Radiation Force Impulse (ARFI), m/s
Pinto51

30

42

94

0.76

AUROC, area under the receiver operating characteristic curve; kPa, kilopascal; PPV, positive predictive value; NPV, negative predictive value; NR, not reported; Sen,
sensitivity; Spe, specificity
Note: AUROC greater than 0.8 represents good accuracy of the test. High sensitivity is helpful for screening tests, and high specificity is helpful for diagnostic tests.
aData were presented for 2 groups of LT children with (n=26) and without (n=15) concurrent acute liver rejection. Patients with concurrent acute liver rejection reportedly had
lower liver stiffness values; hence, the liver stiffness cutoff was computed from 15 patients with no rejection.
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Table 9. Summary of the studies examining the diagnostic performance of selected
serum-based fibrosis markers for assessing hepatic graft fibrosis in LT children
Study

Serum

F2

N

markers

Sen

Spe

PPV

NPV

Cutoff

(%)

(%)

(%)

(%)

AUROC

26

88

42

79

0.53

Lee49

APRI

79

0.99

Vinciguerra50

APRI

36

NR

D'Souza52

APRI

39

0.45

67

79

67

79

0.74

Pinto51

APRI

30

0.4

83

58

31

94

0.74

1.1

100

63

40

100

0.69

AST/ALTa
Goldschmidt48

ELF

23

see

FibroTest

28

noteb

0.59

see noteb

ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST-to-platelet index; AUROC,
area under the receiver operating characteristic curve; ELF, enhanced liver fibrosis test; PPV, positive
predictive value; NPV, negative predictive value; NR, not reported; Sen, sensitivity; Spe, specificity.
Note: AUROC greater than 0.8 represents good accuracy of the test. High sensitivity is helpful for
screening tests, and high specificity is helpful for diagnostic tests.
aThe combination of AST/ALT ratio and acoustic radiation force impulse (ARFI) elastography improved
AUROC to 0.83, p= 0.013.
bCutoffs for biomarkers based on the manufacturers' references: ELF, <7.7 mild or no fibrosis, 7.7–9.8
moderate fibrosis, and >9.8 severe fibrosis; FibroTest, the score can take values from 0 to 1. The AUROC
calculation for both FibroTest and ELF did not show any diagnostic value, and neither FibroTest nor ELF
were able to discriminate between different stages of fibrosis (data not reported by the authors).

Discussion
Non-invasive tests for assessing liver fibrosis have been extensively investigated in nontransplant patients with chronic liver disease. Adult literature has demonstrated that
ultrasound elastography is a validated measure for assessing hepatic fibrosis that has
been increasingly used in clinical practice, especially in patients with chronic hepatitis C
infection and non-alcoholic fatty liver disease. Among the elastography techniques, TE is
the most validated and widely used method, although its diagnostic performance has
remained limited to diagnosing intermediate stages of hepatic fibrosis. An accurate
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measurement of LS by TE requires stringent criteria, which include (1) the ratio of
successful measurements to the total number of acquisitions is  60%, and (2) the IQR
for measurements is within 30% of the median value; of these, the latter is the most
important criterion.53 It was recommended that 10 valid measurements be obtained in
the right liver lobe with the patient lying supine, using an appropriate probe size
according to the patient's chest circumference.
Published studies have shown that cutoffs for significant fibrosis vary by
elastography technique as well as patient population, and overall, all modalities are
better at diagnosing cirrhosis (F4) than significant fibrosis (F2).38 A meta-analysis of 40
adult studies comparing TE with liver biopsy, TE reportedly had a sensitivity of 79% and
a specificity of 78% for stage 2 fibrosis at a cutoff of 7.2 kPa, whereas it had a sensitivity
of 83% and a specificity of 89% for cirrhosis at a cutoff of 14.5 kPa. 38,41 A recent
systematic review of 27 pediatric studies examining different types of ultrasound
elastography in children with various chronic liver diseases, of which 12 studies
compared elastography with liver biopsy, has also reported that cirrhosis was correctly
diagnosed by elastography, whereas it was more difficult to assess severe fibrosis
accurately.42 Moreover, ultrasound elastography was less accurate for distinguishing
between no fibrosis, mild, and moderate stages of fibrosis in these children, and no
fibrosis-specific cutoffs were proposed.42 In healthy children, among 14 studies in which
results of ultrasound elastography in children with no liver disease were compared with
those in adults, LS values in healthy children were reported to be comparable with those
in adults,42 although several other pediatric studies have shown a tendency of increasing
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LS with age.54-56 Additionally, the reference values for normal LS vary by elastography
techniques, with 2D-SWE reportedly having lower LS measurements compared to pointSWE and TE.56
The diagnostic accuracy of ultrasound elastography and selected serum markers
have also been examined in the post-LT setting. A recent meta-analysis43 of 24 studies
(including 3 in pediatric LT) comparing the diagnostic accuracy of TE, APRI, and FIB4 with
liver biopsy in the setting of post-LT demonstrated that TE performed best to diagnose
significant recurrent fibrosis (F2-F4) after LT; there was no significant difference in the
diagnostic performance between the two biomarkers APRI and FIB4. The present
scoping review represents the first attempt to scope the literature relevant to hepatic
graft fibrosis exclusively in LT children. Despite the limited number of studies in the
pediatric LT population, our findings demonstrated that TE has remained the most
widely used elastography technique in LT children, with a good ability to distinguish
children with hepatic graft fibrosis (F1) from those with no fibrosis. The optimal TE
cutoff value for the discrimination of hepatic graft fibrosis (F1) in this review ranged
from 7.05 to 8 kPa, which was a narrower range than reported in a recent metaanalysis,43 despite similarly different post-transplant time points for assessment of
hepatic fibrosis. This range, however, appeared to be slightly higher than that reported
in healthy children (4.3-5.0 kPa, with upper limits reportedly ranging from 5.63 to 6.5
kPa)42,54,56-58 and non-transplant children with various chronic liver diseases (4.9-6.1
kPa).42,59 Moreover, it was challenging to propose fibrosis specific cut-points because
the LS cutoff values for different stages of hepatic graft fibrosis ranged widely across the
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studies, and there was considerable overlap in the mild to significant fibrosis groups
(F1 and F2) (Table 8). Only one pediatric study examined the diagnostic accuracy of
ARFI elastography, and none has investigated the diagnostic accuracy of 2D-SWE in the
setting of pediatric LT.
The serum-based fibrosis markers APRI and FIB4 have been investigated in adult
LT recipients for diagnostic and prognostic purposes because interval changes in these
biomarker values have been shown to predict long-term patient and graft outcomes.60
However, the applicability and usefulness of these biomarkers in LT children remain
under-investigated. Moreover, the reliability of these biomarkers in the pediatric LT
population has been questioned because some of the variables used to calculate these
scores might be affected by conditions other than hepatic fibrosis, such as persistent
thrombocytopenia secondary to splenomegaly due to post-transplant portal vein
thrombosis, thrombocytosis in combined LSBT children who often have concurrent
splenectomy at the time of transplant, or the fact that the patient's age does not
correspond to the hepatic graft's age. Accordingly, the present review demonstrated
that few studies employed serum-based fibrosis markers for predicting hepatic graft
fibrosis in LT children. APRI was most commonly included in studies using biomarkers, all
of which showed a heterogeneous diagnostic accuracy and a wide range of cutoff values
for predicting significant hepatic graft fibrosis. The AST/ALT ratio performed poorly
alone (one study), but its diagnostic accuracy significantly improved when combined
with ARFI elastography. The use of patented panels of fibrosis markers, such as ELF and
FibroTest, remains limited in the pediatric population. Only one study included in this
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review examined the diagnostic accuracy of ELF and FibroTest, which demonstrated that
their normal or cutoff values for various stages of fibrosis could not be transferred from
healthy children to LT children. Additionally, a previous study that used FibroTest in 5 LT
children reported a concordance rate of only 25% between FibroTest and liver biopsy. 61
The present review had several strengths. Unlike the previous meta-analysis that
included both pediatric and adult LT studies with highly heterogeneous study
populations due to mixed etiologies of liver disease in both adults and children (i.e., a
high proportion of HCV infection and alcoholic liver disease in adults), we included only
pediatric studies with more comparable primary liver etiologies. Moreover, we applied
deliberate inclusion criteria and also included the studies that were published in the
abstract form to scope the pediatric literature. To the best of our knowledge, this review
was the first summary of the non-invasive evaluation of hepatic graft fibrosis in LT
children. It included the highest number of pediatric studies that reported the diagnostic
accuracy of these non-invasive tests for assessing hepatic graft fibrosis in these
transplant recipients.
Limitations of the present review were mainly related to the nature of its scoping
review. We did not appraise the methodological quality of each individual study because
this scoping review aimed to capture as many as possible the studies that employed
elastography and selected serum-based fibrosis markers in pediatric LT, using liver
biopsy as the reference test.
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Conclusions
Although there was a limited number of studies examining the usefulness of noninvasive tests for assessing hepatic graft fibrosis in LT children, available literature
suggested that TE in post-LT has similar diagnostic value and limitations as in the nontransplant setting. A specific LS cutoff value for predicting hepatic graft fibrosis (F1)
should be defined based on the context in which TE is intended to be used, taking into
account the false positive and false negative rates. If TE is to be used as a screening tool,
an optimal LS cutoff should have a high sensitivity and a reasonable specificity to
capture as many patients with hepatic fibrosis as possible so that they can be closely
monitored for fibrosis progression. Once it comes to assessing the need for an invasive
liver biopsy, a LS cutoff with a high specificity would be preferred to avoid children
undergoing an unnecessary liver biopsy. Accordingly, the LS value of 7.05 kPa, with a
sensitivity of 80% and a specificity of 100%, might be a suitable TE cutoff for
distinguishing LT children with hepatic graft fibrosis (F1) from those with no fibrosis,
but this cutoff value would need to be validated in a prospective, large-scale study to
determine if TE could be used as a screening tool in LT children. There is undoubtedly a
need to define the optimal LS cutoff values for various stages of hepatic graft fibrosis,
considering the differences between different types of liver grafts and the history of
post-LT complications. It is also important to validate an optimal LS cutoff value for
predicting significant hepatic graft fibrosis (F2) to inform clinicians when a liver biopsy
is needed and when to initiate appropriate intervention at a stage where the fibrosis is
not yet clinically apparent but has the potential for progression. Future studies should
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also look into the diagnostic performance of other newer elastography techniques, such
as 2D-SWE, in the setting of pediatric LT. Longitudinal studies would also be helpful to
investigate if ultrasound elastography could be incorporated in the follow-up of children
after LT, to identify hepatic graft fibrosis at an early stage and monitor its progression
over time, as well as to determine if a meaningful change in LS value from baseline
could identify patients at risk for fibrosis progression. Moreover, given the
unsatisfactory diagnostic accuracy of current serum-based fibrosis markers in LT
children, the development of new serum-based markers might be warranted to assess
better hepatic graft fibrosis in this pediatric LT population.
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Chapter 3: Diagnostic Performance of 2-Dimensional Shear Wave
Elastography and Serum-Based Fibrosis Markers for Evaluation of
Hepatic Graft Fibrosis in Pediatric Liver-Inclusive Transplant
Recipients
Background
Ultrasound-based elastography has been a well-accepted non-invasive tool to assess
hepatic fibrosis in patients with chronic liver disease and recently in LT recipients.
Ultrasound-based elastography measures LS based on the generation of shear wave by
an external or internal mechanical push and is termed shear wave elastography (SWE).53
Vibration-controlled transient elastography (i.e., TE) is a single-dimensional ultrasoundbased technique using an external mechanical push to generate shear waves that
propagate into the liver parenchyma. Acoustic radiation force impulse (ARFI)
elastography uses shear waves that are generated by an internal acoustic push pulse
made by the acoustic radiation force impulse directly into the liver parenchyma, and the
assessment of LS is then made either at one point as in point-SWE, or using several ARFI
lines to obtain quantitative images of the elasticity as in 2D-SWE.38,53,62 Although TE is
the most validated and widely used method to assess hepatic fibrosis, the newer
ultrasound-based elastography technique 2D-SWE has recently been shown to perform
better than TE in predicting both significant hepatic fibrosis and cirrhosis in adults. 63 2DSWE technique has the advantage that the elasticity is displayed using a color-coded
image superimposed on a B-mode image, and simultaneously, a quantitative LS
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estimation can be obtained in a region of interest within the liver in real-time. To date,
2D-SWE has not been examined to assess hepatic fibrosis in the pediatric LT setting.
Given its advantage and good diagnostic performance reported in a recent metaanalysis,63 we hypothesized that 2D-SWE could also be used to predict hepatic graft
fibrosis in the pediatric LT population, either as a single test or in combination with
serum-based fibrosis markers. In this study, we aimed to evaluate the diagnostic
performance of 2D-SWE and selected serum fibrosis markers in predicting hepatic graft
fibrosis in pediatric liver-inclusive transplant recipients, using liver biopsy as the
reference standard.

Methods
Study design and patient population
This prospective, cross-sectional pilot study was approved by the UNMC Institutional
Review Board. Between May 2018 and August 2021, we enrolled consecutive children
younger than 19 years who had received a primary liver-inclusive transplant (LT or LSBT)
and underwent a liver biopsy performed for clinical indications. Patients with
obstructive cholestasis, non-alcoholic fatty liver disease, chronic viral hepatitis B or C, or
congestive heart failure were excluded because these conditions may contribute to LS.
Data collection
We collected data on patient demographics, transplant-related information, and
laboratory data at the time of liver biopsy. Serum-based fibrosis markers, such as
AST/ALT ratio, APRI, and FIB4, were calculated using standard formulas (Table 6).
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Additionally, because the patient’s age may not correspond to the hepatic graft’s age50
and we recently demonstrated that increasing donor-to-recipient age ratio had a trend
to be associated with significant hepatic graft fibrosis,64 a modified FIB4 score (defined
as graft FIB4) was also calculated using the hepatic graft’s age instead of the patient’s
age at the time of liver biopsy.
Liver histopathology
Hepatic fibrosis was assessed using Masson’s trichrome stain and staged by a single,
experienced transplant pathologist who was blinded to the results of 2D-SWE. The
Batts-Ludwig semiquantitative classification system was used, which classifies fibrosis
into five stages: F0, no portal fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis
with few septa; F3, portal fibrosis with numerous septa, no cirrhosis; and F4, cirrhosis.
Hepatic fibrosis was further classified as clinically significant fibrosis if it was staged at or
above F2 (F2).
Liver stiffness measurements
LS was obtained by a single technician using the 2D-SWE technique as previously
described.53 2D-SWE is a newer elastography method using several lines of acoustic
radiation force impulse to generate shear waves over a large region of interest within
the liver in real-time to obtain quantitative images of the elasticity.53,62 It has a high
intra- and inter-observer reproducibility with good to excellent intra- and inter-class
correlation coefficients.65 Its scan-rescan repeatability performed by the same operator
on the same day has been reported to be excellent, with comparable intraclass
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correlation coefficient between expert and novice operators (0.95 vs. 0.93,
respectively).62,66 All patients had their 2D-SWE exams scheduled on the day of liver
biopsy, or if this was practically impossible, within 6 months of liver biopsy. Patients
who underwent 2D-SWE immediately before the liver biopsy procedure were fasting
overnight; otherwise, they were fasting for at least 2 hours, as tolerated.67 Briefly, with
the patient lying supine and the right arm in maximal abduction, the examination was
performed perpendicular on the liver surface through intercostal and/or sub-xiphoid
approaches using the standard technique. In the case of whole liver graft, the
measurements were performed on the right liver lobe because previous studies have
shown that LS value obtained from the right liver lobe is more accurate in diagnosing
hepatic fibrosis,68-70 and because liver biopsy is usually performed on the right liver lobe.
LS values were expressed as meters per second (m/s), which could also be transformed
to kPa. For each patient, 6-10 measurements were recorded, and the median value
(IQR) was used to express the representative value. LS value was considered unreliable if
IQR/median value was 0.30.53 All 2D-SWE results were reviewed by a single radiologist.
The technician and radiologist were blinded to the results of liver biopsy.
Post-transplant protocol
The standard immunosuppression protocol and prophylactic medications were
described previously.64 Liver biopsy was performed only for clinical indications, such as
for elevated transaminases to rule out acute liver rejection or other etiologies. All LSBT
children underwent weekly ileoscopy during the first month post-transplant for
intestinal rejection surveillance.
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Statistical analysis
Data were analyzed using SAS OnDemand for Academics (SAS Institute Inc., Cary, NC,
USA). Patient characteristics were reported as frequencies and percentages, and
medians and IQRs. Groups of patients were compared using the Fisher’s exact test for
categorical variables and using the Mann-Whitney U test or Kruskal-Wallis test for
continuous variables, as appropriate. Areas under the receiver operating characteristic
curves (AUROC) and the 95% CI of the AUROC values were calculated to evaluate the
ability of 2D-SWE, AST/ALT ratio, APRI, FIB4, graft FIB4, and their combinations to
discriminate patients with significant hepatic graft fibrosis (F2) from those with no-mild
fibrosis (F0-F1). A test is considered excellent if an AUROC is 0.9-1, good if an AUROC is
0.8-0.9, fair if an AUROC of 0.7-0.8, and poor if an AUROC is 0.6-0.7. Youden’s index was
used to define the optimal LS and serum marker values for predicting the presence of
significant hepatic graft fibrosis by maximizing the probability of a true positive rate (i.e.,
sensitivity) and minimizing the probability of a false positive rate (i.e., 1-specificity).
Additionally, descriptions of the operative characteristics of these non-invasive tests for
the detection of significant hepatic graft fibrosis, such as sensitivity, specificity, PPV, and
NPV, were computed, using liver biopsy as the gold standard for the diagnosis of
fibrosis. A p-value of less than 0.05 was considered statistically significant.
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Results
Patient characteristics
Twenty-two children (13 males, 8 LSBT) met the inclusion criteria. The median (IQR)
patient’s age at the time of transplant was 1.4 (6.5) years. As shown in Table 10, biliary
atresia was the most common primary liver disease in LT children, whereas all LSBT
patients had intestinal failure-associated liver disease. Eighteen (81.8%) children
received a whole liver graft, including 8 LSBT patients. At the time of liver biopsy, most
patients were maintained on a tacrolimus-based regimen; fourteen (63.6%) patients
were also on low-dose steroids, at a median (IQR) dose of 0.3 (0.1) mg/kg/day (Table
10).
All liver biopsies were performed for evaluation of elevated transaminases.
Seven (31.8%) children had concurrent acute liver rejection (5 patients with mild
rejection and 2 patients with moderate rejection). Thirteen (59.1%) patients had hepatic
fibrosis (F1), and four (18.2%) children had significant fibrosis (F2), after a median
(IQR) post-transplant time of 10.5 (107.0) months. There was no significant difference in
the percentages of concurrent acute liver rejection, portal and/or lobular inflammation
between patients with and without significant fibrosis.
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Table 10. Patient characteristics
Total

Significant fibrosis

p-value

(n=22)

No (n=18)

Yes (n=4)

Male, n (%)

13 (59.1)

11 (61.1)

2 (50.0)

1.00

Age at transplant (years), median (IQR)

1.4 (6.5)

1.3 (6.5)

2.2 (6.3)

0.65

Clinical characteristics

Primary liver disease, n (%)

1.00

Biliary atresia

6 (27.3)

5 (27.8)

1 (25.0)

Acute liver failure

3 (13.6)

3 (16.7)

0 (0.0)

Intestinal failure-associated liver disease

8 (36.4)

6 (33.3)

2 (50.0)

Other

5 (22.7)

4 (22.2)

1 (25.0)

Primary intestinal disease, a n (%)

0.78

Necrotizing enterocolitis

2 (22.2)

2/7 (28.6)

0/2 (0.0)

Intestinal atresia

4 (44.5)

2/7 (28.6)

2/2 (100.0)

Gastroschisis

1 (11.1)

1/7 (14.2)

0/2 (0.0)

Other

2 (22.2)

2/7 (28.6)

0/2 (0.0)

Liver graft type, n (%)

0.58

Full-size

18 (81.8)

15 (83.3)

3 (75.0)

Reduced-size/split

1 (4.6)

1 (5.6)

0 (0.0)

Living-related

3 (13.6)

2 (11.1)

1 (25.0)

Donor-to-recipient age ratio, median (IQR)

0.8 (3.2)

0.8 (3.2)

0.8 (24.3)

0.88

Cold ischemia time (hours), median (IQR)

6.1 (1.9)

6.1 (1.7)

6.4 (6.3)

0.96

Immunosuppression, n (%)

0.41

Tacrolimus only

15 (68.2)

11 (61.1)

4 (100.0)

Tacrolimus and other

6 (27.3)

6 (33.3)

0 (0.0)

Non-tacrolimus

1 (4.6)

1 (5.6)

0 (0.0)

14 (63.6)

13 (72.2)

1 (25.0)

0.12

0.3 (0.1)

0.3 (0.1)

0.3

0.71

9 (40.9)

6 (33.3)

3 (75.0)

0.26

Steroids use at the time of biopsy, n (%)
Median (IQR) dose (mg/kg/d)
Post-transplant complications, n (%)
Liver complications
Acute liver rejection b
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Total

Significant fibrosis

p-value

(n=22)

No (n=18)

Yes (n=4)

Chronic liver rejection

2 (9.1)

1 (5.6)

1 (25.0)

0.34

PTLD in liver

1 (4.6)

0 (0.0)

1 (25.0)

0.18

Biliary complications

1 (4.6)

1 (5.6)

0 (0.0)

1.00

Vascular complications

2 (9.1)

2 (11.1)

0 (0.0)

1.00

Viral hepatitis

2 (9.1)

2 (11.1)

0 (0.0)

1.00

Acute cellular intestinal rejection

7/8 (87.5)

5/6 (83.3)

2/2 (100.0)

1.00

Antibody-mediated intestinal rejection

1/8 (12.5)

1/6 (16.7)

0/2 (0.0)

1.00

Chronic intestinal rejection

2/8 (25.0)

0/6 (0.0)

2/2 (100.0)

0.04

PTLD in intestine

1/8 (12.5)

1/6 (16.7)

0/0 (0.0)

1.00

Intestinal complications

Laboratory tests at the time of liver biopsy, median (IQR)
AST (IU/L)

159 (208)

121 (167)

262 (265)

0.11

ALT (IU/L)

215 (205)

215 (193)

300 (359)

0.54

GGT (IU/L)

126 (395)

147 (395)

83 (298)

0.91

Total bilirubin (mg/dL)

0.5 (0.5)

0.5 (0.8)

0.6 (0.8)

0.79

Platelet count (x 1000/mm3)

244 (198)

272 (304)

231 (157)

0.39

a Included

8 liver-small bowel transplant patients and 1 liver transplant patient with shortbowel syndrome
b Included patients who had prior acute liver rejection (n=2) and concurrent acute liver
rejection (n=7) at the time of liver biopsy

Serum-based fibrosis markers
All patients had a blood sample collected on the day of liver biopsy. The median (IQR)
APRI was significantly higher in patients with significant hepatic fibrosis compared to
those with no-mild fibrosis (3.7 [4.4] vs. 1.3 [1.3], p=0.03). As shown in Figure 8, the
AUROC of APRI to distinguish patients with significant fibrosis from those with no-mild
fibrosis was 0.85 (95% CI: 0.67-1.00, p=0.0001). The optimal APRI cutoff value for
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detecting significant hepatic graft fibrosis was 1.83, with a sensitivity of 100%, a
specificity of 67%, a PPV of 40%, and an NPV of 100%.
There was no significant difference in the median AST/ALT ratio and FIB4
between patients with and without significant fibrosis. The AUROC of AST/ALT ratio for
predicting significant fibrosis was 0.71 (95% CI: 0.32-1.00, p=0.29, Figure 8). Although it
was not statistically significant, the optimal AST/ALT ratio cutoff value of 0.90 was able
to distinguish patients with and without significant fibrosis, with a sensitivity of 75%, a
specificity of 72%, a PPV of 38%, and an NPV of 93%. The AUROC of FIB4 for the
detection of significant fibrosis was 0.76 (95% CI: 0.53-1.00, p=0.03, Figure 8); the
optimal FIB4 cutoff of 0.74 yielded a sensitivity of 75%, a specificity of 78%, a PPV of
43%, and an NPV of 93%. When FIB4 was calculated based on the hepatic graft’s age
(graft FIB4), there was a significant difference in the median graft FIB4 between patients
with and without significant fibrosis: 1.7 (2.1) vs. 0.2 (0.4), p=0.03. Accordingly, its
AUROC improved to 0.85 (95% CI: 0.68-1.00, p<0.0001, Figure 8); its optimal cutoff
value of 0.61 yielded a sensitivity of 100%, a specificity of 78%, a PPV of 50%, and an
NPV of 100% for the detection of significant fibrosis.
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Figure 8. The AUROC of APRI, AST/ALT ratio, FIB4, and graft FIB4 for the detection of
significant hepatic graft fibrosis

2D-shear wave elastography
Four children had technical or breathing issues during their 2D-SWE exams and were
excluded owing to unreliable LS values. Except for 4 out-of-state patients who had their
2D-SWE exams performed within 4-7 months of liver biopsy, other patients had 2D-SWE
performed on the same day or within one month of liver biopsy. The median (IQR) time
between liver biopsy and 2D-SWE was 19 (54) days. The median patient's age and
hepatic graft's age at the time of 2D-SWE were 8.9 (range: 0.6 - 18.7) years and 9.0
(range: 0.6 - 64.5) years, respectively. The median (IQR) AST and ALT at the time of liver
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biopsy were 159 (208) IU/L and 215 (205) IU/L, respectively; however, at the time of 2DSWE, the median (IQR) AST and ALT were almost within normal limits at 39 (66) IU/L and
43 (48) IU/L, respectively. There was no significant difference in the median (IQR) LS
value between LSBT and LT children (1.4 [0.2] vs. 1.4 [0.48] m/s, p=0.60, Figure 9),
between whole liver and partial liver grafts (1.4 [0.4] vs. 1.3 [0.4] m/s, p=0.44), or
between patients with any fibrosis stage (F1) and those with no fibrosis (1.3 [0.5] vs.
1.3 [0.5] m/s, p=0.93). Additionally, there was no significant difference in the median LS
value between groups of children aged younger than 4 years, 4 to younger than 12
years, and older than 12 years (1.3 vs. 1.4 vs. 1.5 m/s, respectively, p=0.69), or between
groups of children with hepatic graft's age younger than 4 years, 4 to younger than 12
years, 12 to younger than 19 years, and older than 19 years (1.4 vs. 1.3 vs. 1.5 vs. 1.4,
respectively, p=0.75). Moreover, further analysis based on histopathologic findings
revealed no significant difference in the median LS value between patients with and
without concurrent acute liver rejection and between patients with various grades of
portal or lobular inflammatory activity. Of note, among 7 patients with concurrent acute
liver rejection, 2D-SWE was performed on the same day of liver biopsy in 2 children;
otherwise, it was performed after the rejection had been treated and improved, within
an average time of 29 days following liver biopsy. Additionally, in 2 children who had
moderate acute liver rejection, LS measurements were obtained after the treatment for
rejection had been completed with a 3-day course of intravenous methylprednisolone,
at 4 days and 110 days following their liver biopsies.
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Figure 9. Comparison of liver stiffness measurements between LT and LSBT children

As shown in Figure 10, the AUROC of 2D-SWE for distinguishing children with
significant fibrosis from those with no-mild fibrosis was 0.80 (95% CI: 0.51-1.00,
p=0.046). The LS cutoff value of 1.2 m/s (4.2 kPa) yielded a sensitivity of 67%, a
specificity of 87%, a PPV of 50%, and an NPV of 93%. Of note, 3 children had significantly
discrepant LS values and fibrosis stages: 2 LT children had high LS values (1.9 m/s) and
no fibrosis on liver biopsy, whereas one LSBT patient had low LS value (1.1 m/s) and
histologic evidence of advanced fibrosis/early cirrhosis. This LSBT patient had been
treated for de novo autoimmune hepatitis, who also developed chronic rejection of liver
and intestinal grafts and has been listed for a repeat LSBT. The other 2 LT patients had
their 2D-SWE exams performed at approximately 3 weeks and 2.3 months posttransplant; their liver biopsies reported preservation-reperfusion injury and nonspecific
hepatitis, respectively.
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Figure 10. The AUROC of 2D-SWE and its combination with APRI and/or FIB4 for the
detection of significant hepatic graft fibrosis

Combinations of 2D-SWE and serum-based fibrosis markers
The paired combinations of 2D-SWE and APRI or FIB4 slightly improved the AUROC of
2D-SWE to 0.82 (95% CI: 0.46-1.00, p=0.08) and 0.87 (95% CI: 0.64-1.00, p=0.002),
respectively (Figure 10). When 2D-SWE was combined with both APRI and FIB4, its
AUROC also slightly improved to 0.84 (95% CI: 0.58-1.00, p=0.01, Figure 10).
Additionally, the AUROC of 2D-SWE improved to 0.87 (95% CI: 0.59-1.00, p=0.009) when
it was combined with graft FIB4 and to 0.84 (95% CI: 0.53-1.00, p=0.03) when it was
combined with both APRI and graft FIB4 (Figure 11).
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Figure 11. The AUROC of 2D-SWE and its combination with graft FIB4 and/or APRI for
the detection of significant hepatic graft fibrosis

Discussion
Pediatric LT has been highly successful, with 1- and 10-year patient and graft survivals
reported at greater than 90% and greater than 80% in most pediatric LT programs,
respectively.1,71 Although clinical outcomes of LSBT children have improved over the
past decade, patient and graft survivals in LSBT children remain inferior compared to LT
children, with 1-, 5-, and 10-year patient and graft survivals of 77%, 58%, 47%, and 71%,
50%, 41%, respectively.2 Long-term hepatic graft outcome depends on multiple factors,
such as disease recurrence, biliary and/or vascular complications, de novo autoimmune
hepatitis, graft dysfunction, and chronic rejection. Hepatic graft fibrosis is a common
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histologic finding in liver-inclusive transplant children and has been reported even in
patients with normal hepatic graft function and normal or nearly normal
transaminases.3,7 We recently reported that 81.6% of LT and 70.2% of LSBT children
developed hepatic graft fibrosis after a median time of 2.5 years and 2.6 years posttransplant, respectively.64 Consequently, this may affect long-term graft and patient
outcomes.
Because of the known limitations of liver biopsy,13,14,16,72-74 there has been an
increasing interest in non-invasive tests, such as serum-based fibrosis markers and
elastography, to assess and monitor the progression of hepatic fibrosis in both nontransplant and LT settings. Despite a limited number of studies investigating the
usefulness of non-invasive tests to assess hepatic graft fibrosis in the pediatric LT
population, our recent scoping review demonstrated that TE remains the most widely
used elastography technique in LT children, and no study has previously reported the
diagnostic performance of 2D-SWE in the pediatric LT setting.75 The advantage of 2DSWE over TE is that it is integrated into a conventional ultrasound system and can be
performed in different locations within the liver in real-time; therefore, it offers the
added benefit of performing a complete liver ultrasound. TE is also limited by the
narrow intercostal spaces in small children or high body mass index in obese patients,
the presence of ascites, or post-transplant altered liver anatomy. To our knowledge, the
current prospective study is the first report on the diagnostic performance of 2D-SWE
and its combination with serum-based fibrosis markers for predicting significant hepatic
fibrosis in both LT and LSBT children, using liver histology as the reference standard.
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The serum-based fibrosis markers AST/ALT ratio, APRI, and FIB4 have been
examined in pediatric LT recipients.48-52 The advantage of using these biomarkers is that
serum transaminases and platelet count are part of the routine laboratory evaluation
with no additional cost. Among the examined biomarkers, APRI was the most commonly
used marker but has shown a heterogenous diagnostic performance and a wide range of
cutoffs in predicting significant hepatic graft fibrosis.50-52,75,76 In contrast with previous
studies that reported a fair AUROC (0.74) for APRI to predict significant hepatic graft
fibrosis,51,52 the present study has shown a good AUROC (0.85) and that the optimal
APRI cutoff value of 1.83 yielded a sensitivity of 100% and a specificity of 67% to predict
significant hepatic graft fibrosis. The AST/ALT ratio was investigated in only one
pediatric study that showed a poor AUROC of 0.69 for predicting significant hepatic graft
fibrosis.51 Consistently, our findings also confirmed its poor diagnostic performance,
with an AUROC of 0.71 when it was used as a single test. Furthermore, in contrast with
the only study examining FIB4 in LT children that showed a poor AUROC (0.62) for FIB4
to predict significant graft fibrosis,76 we have shown for the first time the usefulness of
FIB4 in the pediatric LT setting, especially using the hepatic graft’s age instead of the
patient’s age to calculate graft FIB4. We demonstrated that graft FIB4 had a good
AUROC of 0.85 to distinguish children with significant hepatic graft fibrosis from those
with no fibrosis or mild fibrosis.
Our results indicated that 2D-SWE is feasible in both LT and LSBT children, and
there was no significant difference in the median LS value between these patient
populations. 2D-SWE is also practically feasible in children with left lateral segment liver
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graft (split liver or living donor liver), and there was no significant difference in the
median LS value between whole liver and partial liver grafts. Although the effect of age
on LS values has not been reported in the pediatric LT setting, published literature
reported conflicting results on the impact of age on LS values measured by various
elastography techniques in healthy children and children with chronic liver disease.
While a previous study comparing LS values between point-SWE and 2D-SWE in healthy
children, using TE as the reference, reported that LS values increased with age,56 other
studies did not support this finding.57,77-79 Consistent with the latter studies, we did not
find a significant difference in the LS value across the age groups in our cohort.
Like other elastography techniques, 2D-SWE remained limited to distinguishing
between no fibrosis, mild, and moderate stages of fibrosis, and there was considerable
overlap in the mild to significant fibrosis stages (F1 and F2). This could explain a nonsignificant difference in the median LS value between patients with any fibrosis stage
(F1) and those with no fibrosis, owing to an overrepresentation of patients with mild
fibrosis (F1) in our cohort. Nevertheless, 2D-SWE was able to distinguish children with
significant hepatic graft fibrosis (F2) from those with no-mild fibrosis (F0-F1) with a
good AUROC of 0.80, and its diagnostic performance further improved when combined
with serum markers APRI and/or FIB4. The LS cutoff value of 1.2 m/s (4.2 kPa) was lower
than that reported in previous studies that used TE (6.5-7.25 kPa)76,80 or point-SWE (1.51.57 m/s)51,69 to detect significant fibrosis in LT children. Notably, the reference values
for normal LS reportedly vary by elastography techniques as well as patient populations.
A previous pediatric study has demonstrated that the 2D-SWE technique yielded
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significantly lower LS values than TE and point-SWE, and the median LS value for 2DSWE was reported at 3.3 (IQR: 2.7-4.3) kPa for normal healthy children.56 Unlike nontransplant children, LS value obtained in LT/LSBT children can be affected by various
factors, such as concurrent acute liver rejection, vascular/biliary complications, posttransplant altered liver anatomy, and the influence of scar tissue and/or the shape of
the liver graft. Among a limited number of studies investigating the diagnostic
performance of elastography in the pediatric LT population, only one study compared LS
value obtained by TE between LT and healthy children; it reported a slightly higher LS
value in LT children with normal liver function test than in healthy children.48 To date,
the normal 2D-SWE LS value for LT children has not yet been defined. Whether the
normal LS range obtained by 2D-SWE in LT children differs from that in healthy children
warrants further investigation with a larger cohort that includes a control group of
healthy children in addition to LT children. Moreover, a common limitation of the
elastography techniques across pediatric studies has been a high NPV but a lower
PPV;48,51,76,80 therefore, strategies to combine LS measurement with other markers
might help boost the PPV. Furthermore, a specific LS cutoff should be determined based
on the context in which the elastography technique is intended to be used, taking into
account the false positive and false negative rates. If 2D-SWE is to be used as a
screening tool, an optimal LS cutoff should have a high sensitivity and a reasonable
specificity to capture as many patients with significant fibrosis as possible so that they
can be closely monitored for fibrosis progression. Once it comes to assessing the need
for an invasive liver biopsy, a LS cutoff with a high specificity would be preferred to
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avoid children undergoing an unnecessary liver biopsy. Accordingly, the LS value of 1.2
m/s might be a suitable 2D-SWE cutoff, but this cutoff value would need to be validated
in a larger cohort to determine if 2D-SWE could be used as a screening tool in liverinclusive transplant children.
The strengths of our study were that this is the first report on the usefulness of
2D-SWE and serum markers, especially graft FIB4, in both LT and LSBT children, using
liver histology as the reference standard for fibrosis staging. Limitations of the present
study include its small sample size and a small number of patients with significant
hepatic graft fibrosis. The prevalence of significant hepatic graft fibrosis in the current
cohort (18.2%) was lower than in previous studies that examined non-invasive tests in
LT children using liver biopsy as the reference (ranging from 20% to 38%). 50-52,76,80 All
pediatric studies, including the present study, have a different distribution of various
fibrosis stages and a relatively low number of children with significant hepatic graft
fibrosis (F2) and advanced hepatic graft fibrosis (F3). This uneven distribution of
fibrosis stages may have affected the optimal LS cutoff values obtained from the AUROC
across the studies. Additionally, although liver biopsy is used as the reference test, its
accuracy is limited by intraobserver and/or interobserver variation and sampling error
that may result in under- or overestimation of fibrosis stages.14,16,72 Given the small
sample size, we were unable to reliably examine the impact of concurrent acute liver
rejection and/or hepatic inflammation, graft types (whole liver vs. partial liver grafts,
deceased vs. living donor grafts), and transplant types (LT vs. LSBT) on the diagnostic
performance (evaluated by AUROC and its operative characteristics) of 2D-SWE and
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serum markers. Although 7 (31.8%) children in the current cohort had concurrent acute
liver rejection, most patients had their LS measurements at the time when the rejection
had been treated and improved; hence, hepatic inflammation related to acute liver
rejection was unlikely to confound the LS results. Additionally, although we included a
few children who underwent liver biopsy and 2D-SWE earlier than 3 months posttransplant where LS value might be affected by various intra- and/or post-operative
factors (such as ischemia-reperfusion injury, increased portal venous pressure, or
revascularization process, etc.), only one patient in our cohort had liver histologic
evidence for preservation-reperfusion injury, and none had histologic features of
hepatic congestion or biliary complications that might contribute to increased LS;
therefore, they were unlikely to be significant confounders in the LS results.
Furthermore, although our findings demonstrated the usefulness of APRI and FIB4 in the
pediatric LT setting, their applicability should be considered with caution in this patient
population because some of the variables used to calculate these serum fibrosis indexes
might be affected by conditions other than hepatic fibrosis, such as thrombocytopenia
secondary to splenomegaly in the setting of post-transplant portal vein obstruction,
thrombocytosis in LSBT children who often have concurrent splenectomy at the time of
transplant, or a discrepancy between the patient’s age and hepatic graft’s age (older
graft age in LT vs. younger graft age in LSBT children). Nevertheless, our results
remained valid because there was no significant difference in the median platelet count
between children with and without significant hepatic graft fibrosis in our cohort; we
also calculated FIB4 based on the hepatic graft’s age. Lastly, similar to other studies
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investigating non-invasive tests in LT children,48,50,76,80 we performed liver biopsy only
for clinical indications, at the time when all patients had elevated transaminases;
therefore, the reliability and usefulness of these serum markers in the pediatric LT
population warrant further validation in a future study of protocol liver biopsies.

Conclusions
Our results indicated that APRI and FIB4 can accurately predict significant hepatic graft
fibrosis. We suggest calculating FIB4 using the hepatic graft’s age (graft FIB4), as it has
shown a better ability to distinguish children with significant hepatic graft fibrosis from
those with no-mild fibrosis. 2D-SWE may serve as a valuable adjunct tool to detect
significant graft fibrosis, especially when combined with APRI and/or FIB4. These noninvasive tests are not expected to replace liver biopsy but rather help clinicians identify
children who will likely benefit from further investigation, and therefore, reduce the
number of children who would be required to undergo an invasive liver biopsy. A future
prospective, larger scale, longitudinal study should investigate whether 2D-SWE and
these serum markers can be used as single tests or in stepwise combinations to identify
hepatic graft fibrosis at an early stage, monitor its progression, as well as to determine if
a meaningful change in these marker values from baseline could identify patients at risk
for fibrosis progression.
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Chapter 4: The Role of Serum Micro-RNA for Evaluation of Hepatic
Graft Fibrosis and Future Directions
Background
Because of the known limitations of liver biopsy, non-invasive methods such as serumbased fibrosis markers and elastography have been investigated in patients with chronic
liver disease and LT. An ideal biomarker should be disease-specific, sensitive to indicate
tissue-specific injury, easily detectable in serum, urine, or other body fluids, and costeffective. Available serum fibrosis markers can be classified into two categories (Table
6): (1) direct markers investigating the fibrosis process, which reflects extracellular
matrix turnover (e.g., ELF score [commercial panel]), and (2) indirect markers assessing
molecules released into the blood that reflects alterations of hepatic synthetic function
(e.g., AST/ALT ratio, FIB4, APRI, FibroTest [commercial panel]). The limited number of
serum indirect markers thus far investigated in the pediatric LT setting have shown only
a moderate accuracy to discriminate children with significant hepatic graft fibrosis (F2)
from those with no fibrosis or mild fibrosis (F0-F1). Hence, there is an unmet need to
develop new biomarkers to better assess hepatic graft fibrosis in the pediatric LT
population.
Micro-RNAs (miRNAs) are small (18-25 nucleotides), non-coding, endogenous
RNAs that bind to target messenger RNAs, and consequently regulate up to 60% of the
expression of cellular messenger RNAs at the post-transcription level. A single miRNA
can target multiple messenger RNAs, and multiple miRNAs can simultaneously regulate
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a single messenger RNA. These miRNAs play a significant role in many physiological and
pathological processes, including cell differentiation, proliferation, maturation, and
biological homeostasis. Additionally, miRNAs play an essential role in the activation and
regulation of inflammatory responses. Once organs and surrounding tissues experience
an injury, affected cells may release specific miRNAs into the systemic circulation, and as
a result, tissue-specific miRNAs can be detected in serum, urine, or other body fluids.8184

Aside from a subset of miRNAs that might be expressed by multiple types of cells, or

their release might be a consequence of the activation of different cell types,85,86
miRNAs are considered tissue- and disease-specific. Due to their stability in the
circulation as well as tissue and disease specificity, miRNAs have been investigated as
potential biomarkers and mediators in the mechanisms of pathogenesis for a number of
chronic conditions, including chronic liver disease (Table 11).83 For instance, miR-122
accounts for more than half of the miRNAs expressed in the liver and is known to be a
marker of liver injury.87,88
In response to chronic liver injury of any etiology, various signaling pathways
triggered by proinflammatory and profibrotic cytokines are involved in the development
of hepatic fibrosis. These include direct activation, proliferation, and migration of
hepatic stellate cells (HSCs), expression of transforming growth factor beta (TGF-) and
platelet-derived growth factor (PDGF), and expression of genes responsible for
extracellular matrix synthesis of different types of collagens. 89,90 Upon activation, HSCs
become proliferative, increase smooth muscle actin expression, acquire a
myofibroblast-like phenotype, and start producing excess extracellular matrix and
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collagens.91 Activated HSCs, therefore, play a central role in tissue remodeling and
hepatic fibrosis.89,91 During recovery from liver injury, activated HSCs can be cleared by
apoptosis, undergo senescence, or be reversed to an inactivated phenotype, resulting in
the resolution of hepatic fibrosis.91 If liver injury is left untreated, fibrosis progresses and
causes distortion of hepatic architecture, leading to the regenerative nodular formation
and eventually liver cirrhosis.89,91 Additionally, previous studies have demonstrated the
role of miRNAs in the modulation of HSC activation,92-95 and an aberrant miRNA
expression has been shown to be a key pathogenic factor in the development and
progression of hepatic fibrosis.96 Accordingly, prior studies have identified a wide range
of miRNAs responsible for early events of hepatic fibrosis.87,89,96,97 Moreover, various
miRNAs can affect different levels of hepatic fibrogenesis and be categorized into
profibrotic or antifibrotic miRNAs according to their regulatory effects on activated HSCs
(i.e., activation or inactivation of HSCs); profibrotic miRNAs are upregulated, and
antifibrotic RNAs are downregulated during the process of hepatic fibrogenesis (Table
12).90 Furthermore, it has been shown that hepatic fibrosis leads to downregulation of
several miRNAs that target several profibrotic genes at the post-transcription level, and
hence, their overexpression decreases hepatic fibrosis.96
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Table 11. Selected aberrant miRNA expression reported in pediatric chronic liver disease
Liver disease
Biliary atresia

Sample type

Upregulated

Downregulated

Liver tissue98-101

21, 30a, 30b, 30c, 199a-

23b, 24-1, 29b-3p,

3p, 199b-3p, 200b, 222

29c-3p

Serum,

21, 92a-3p, 100-5p, 122- 10b-5p, 23a-3p, 26a-

plasma102-106

5p, 150-3p, 194-5p,

5p, 29c, 126-3p,

200a-3p, 200a, 200b,

140-3p, 142-3p,

429, 432-5p, 574-5p,

370-3p, 744-5p,

4689, let7c-5p

4429
451

Non-alcoholic

Liver tissue107-

21, 146a, 146b, 152,

fatty liver disease

109

200a, 200b, 200c

Cystic fibrosis

Serum110,111

34a-5p, 122, 122-5p,

liver disease
Chronic viral

365a-3p
Plasma112-114

hepatitis B

28-5p, 30a-5p, 30e-3p,

654-3p

99a-5p, 100-5p, 122-3p,
122-5p, 125, 125b-5p,
192-3p, 192-5p, 193b3p, 194-5p, 365a-3p,
378a-3p, 455-3p, 4555p, 483-3p, 574-3p,
855-5p, 1247, let-7c

Table 12. Selected miRNAs involved in hepatic fibrosis
Profibrotic miRNAs91,96,97

Antifibrotic miRNAs91,96,97

(upregulated)

(downregulated)

21, 27a, 27b, 33a, 34a, 34b, 93, 106b, 181b,

15a, 15b, 16, 19b, 29a, 29b, 101b, 107,

199a, 200c, 221, 222, 615

122, 126, 132, 133a, 148a, 150, 194, 195,
200a, 214, 335, 378a, 449, 449a, 483
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Diagnostic application of miRNAs in the LT setting and future directions
Non-invasive tests have been recently investigated as potential biomarkers for
diagnosing acute liver rejection in the LT setting. These include acid labile nitrosocompounds, serum amyloid A protein, guanylate-binding protein-2 mRNA, graft-derived
cell-free DNA, pi-glutathione S-transferase, alpha-glutathione S-transferase,
procalcitonin, peripheral eosinophil count, serum HLA class I soluble antigens,
peripheral T-cell activation, and IL-2 receptor.115 However, none have been translated
into standard clinical use owing to their uncertain diagnostic accuracy or because most
studies had inferior designs. Therefore, liver biopsy currently remains the gold standard
for diagnosing acute liver rejection.
In recent years, miRNAs have emerged as potential novel diagnostic biomarkers
for acute allograft rejection or chronic allograft dysfunction in the setting of solid organ
transplantation.85,116-125 Several serum miRNAs, such as miR-122, miR-146a, miR-148a,
miR-192, and miR-194, have been reported to correlate with hepatic injury and acute
liver rejection in LT recipients.116,118 However, to date, the role of miRNAs in the
development and progression of hepatic graft fibrosis in the pediatric LT population has
not been examined. We hypothesize that the process involving the development of
hepatic graft fibrosis would be similar to that in patients with chronic liver disease, but
the triggers might differ (Figure 12). These may include any post-transplant events
leading to liver injury, such as viral infection, drug-induced liver injury, acute or chronic
liver rejection, autoimmune antibodies in the setting of de novo autoimmune hepatitis,
and donor-specific antibodies. It is unknown if miRNAs would be expressed differently in
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post-transplant hepatic fibrosis compared to hepatic fibrosis related to various chronic
liver diseases and whether their differential expression could be used as potential
biomarkers to detect hepatic graft fibrosis and follow its progression over time. Given
the specific miRNA expression reported in hepatic fibrosis associated with various
pediatric liver diseases,87 a prospective project would be warranted to explore miRNA
profile and expression associated with hepatic graft fibrosis in liver-inclusive transplant
children. We hypothesize that there would be a specific set of serum miRNAs that can
accurately predict various stages of hepatic graft fibrosis in these transplant recipients.
Moreover, further exploration of the correlation between this specific miRNA set and
other serum-based fibrosis markers, 2D-SWE, and/or hepatic miRNAs in future
validation studies would also be helpful in order to develop a prognostic model to
predict advanced hepatic graft fibrosis. Furthermore, as the long-term goal is to develop
a serum-based diagnostic test rather than a tissue-based diagnostic test (to reduce the
number of children undergoing an invasive liver biopsy), it is essential to examine if
circulatory miRNAs of interest correlate well with hepatic fibrosis staging on liver biopsy
and whether the test has the ability to discriminate patients with significant fibrosis
from those with no fibrosis or mild fibrosis. The quantification of hepatic miRNA of
interest in patients who undergo a liver biopsy, however, might help better characterize
the stage of fibrosis as the differential expression of several hepatic miRNAs according
to the stages of fibrosis has been reported in adult patients with chronic hepatitis B and
C,86 and therefore, reduce the risk of misclassification among pathologists. Lastly, if a
specific type of miRNA is identified in children with hepatic graft fibrosis, either
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antifibrotic or profibrotic, this may help future studies investigate its role in the
development and progression of hepatic graft fibrosis. Such a specific type of miRNA
may also be a potential target for future antifibrotic therapy.

Figure 12. Proposed role of micro-RNAs in the development of hepatic graft fibrosis.
HSCs, hepatic stellate cells; TGF-, transforming growth factor beta; PGDF, plateletderived growth factor.
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Conclusions and Perspectives
Hepatic graft fibrosis is a common histologic finding in long-term pediatric LT survivors.
For the first time, we have demonstrated that children with combined LSBT can also
develop hepatic graft fibrosis over time; its prevalence did not differ significantly from
LT children: 70.2% versus 81.6% after a median time of 2.6 years and 2.5 years,
respectively. On multivariate analyses, we have shown that the predictors for hepatic
graft fibrosis differed between LSBT and LT children. While having a history of posttransplant biliary complications was found to be an independent predictor for significant
hepatic graft fibrosis in LT children, AST/ALT ratio was found to be a significant predictor
for significant hepatic graft fibrosis in LSBT children. Additionally, increasing donor-torecipient age ratio and increasing allograft cold ischemia time appeared to be associated
with significant hepatic graft fibrosis in LT children. Therefore, early diagnosis and
aggressive treatment of post-transplant biliary complications as well as strategies to
optimize graft quality might help reduce the prevalence of hepatic graft fibrosis in LT
children. The roles of post-transplant autoimmune antibodies and DSA in the
development and progression of hepatic graft fibrosis have not been investigated,
especially in LSBT children, and therefore warrant future collaborative studies.
Since hepatic graft fibrosis appears to be dynamic over time and the fibrosis
stage could decrease with time, especially in patients with mild fibrosis, it is important
to recognize hepatic graft fibrosis at an early stage in order to develop strategies to halt
its progression or even reverse fibrosis. Unlike patients with inflammatory liver disease
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or acute liver rejection, LT children with hepatic graft fibrosis may have normal graft
function and/or normal or minimally elevated transaminases. While transaminases
might not be helpful to detect and monitor the progression of hepatic fibrosis, several
serum-based fibrosis markers have been investigated for predicting hepatic fibrosis,
although there was a limited number of studies examining the usefulness of these
biomarkers for assessing hepatic graft fibrosis in the pediatric LT population. We have
demonstrated that APRI and FIB4 can accurately predict significant hepatic graft fibrosis
in LT/LSBT children. Particularly, when FIB4 was calculated using the hepatic graft’s age
(graft FIB4), its ability to distinguish children with significant hepatic graft fibrosis from
those with no fibrosis or mild fibrosis improved. Moreover, for the first time, we have
shown the usefulness of 2D-SWE in the pediatric LT setting; 2D-SWE was able to
distinguish children with significant hepatic graft fibrosis from those with no fibrosis or
mild fibrosis with a good AUROC of 0.80, and its diagnostic performance further
improved when combined with serum markers APRI and/or FIB4. These non-invasive
tests, however, are not expected to replace liver biopsy but rather help identify patients
who will likely benefit from further investigation with liver biopsy, and therefore, reduce
the number of children who would be required to undergo an invasive liver biopsy.
Thus, the work in this dissertation advances our understanding of the diagnostic
performance of these non-invasive tests and lays the groundwork for a future larger
scale, prognostic study to examine if 2D-SWE and serum markers can be used as single
tests or in stepwise combinations in order to develop a prognostic model for predicting
advanced hepatic graft fibrosis. A prospective, longitudinal study would also be needed
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to investigate whether 2D-SWE and serum markers can be incorporated in the yearly
follow up of LT/LSBT children to identify hepatic graft fibrosis at an early stage, monitor
its progression, as well as to determine if a meaningful change in these marker values
from baseline could identify patients at risk for fibrosis progression.
Because the current serum-based fibrosis markers have shown only a moderate
accuracy to discriminate children with significant hepatic graft fibrosis from those with
no fibrosis or mild fibrosis, there is an unmet need for the development of new
biomarkers to better assess hepatic graft fibrosis in the pediatric LT population.
MicroRNAs have been shown to play a key role in the pathogenesis of hepatic fibrosis.
Given their tissue and disease specificity, miRNAs recently have emerged as potential
novel biomarkers for hepatic fibrosis in patients with various types of chronic liver
disease. Hence, a prospective study would be warranted to profile serum miRNAs and
measure their expression level in LT/LSBT children with hepatic graft fibrosis. The results
from this miRNA study will further guide future prognostic studies to examine if serum
miRNAs could be used as a single test or in combination with other serum-based
markers and/or elastography to develop a prognostic model for predicting advanced
hepatic graft fibrosis. Furthermore, since miRNA modulation is essential for HSC
activation into proliferative myofibroblasts, a better understanding of serum miRNA
expression in post-transplant hepatic fibrosis will also help develop potential targeted
therapy to prevent or halt the progression of hepatic graft fibrosis in these transplant
recipients.
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